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ABSTRACT  
 
 
 
 
METHODS DEVELOPMENT IN BIOLOGICAL MASS SPECTROMETRY: 
APPLICATION IN GLYCOPROTEOMICS 
 
Proteomics refers to global characterization of the full set of proteins present in a 
biological sample. Various analytical disciplines contribute to proteomics but mass 
spectrometry became method of choice for analysis of complex protein samples. 
Mass spectrometry allows for high throughput analysis of the proteome but, moreover, it 
has the ability to acquire higher-order information such as post-translational 
modifications (PTM). Glycosylation is the most abundant PTM on eukaryotic proteins. 
This dissertation will focus on method development for structural proteomics that 
will be utilized to explain the glycoproteome of obligate intracellular protozoan parasite 
Toxoplasma gondii as a model system. 
Optimization of sample preparation is addressed in the first part of this 
dissertation. Sample preparation for mass spectrometry analysis is a critical step in the 
proteomics workflow because the quality and reproducibility of sample extraction and 
preparation significantly impacts the separation and identification capabilities of mass 
spectrometers. Also, there are problems unique to intracellular parasites as limited 
amount, host cell impurity and choice of the host. The additional obstacle is to extract 
only glycosylated proteins for which there is no one standard method. Here we report the 
optimal sample preparation method utilizing agarose bound Concanavalin A (Con A) 
beads to efficiently pull down glycoproteins, dialyze and analyze them using MuDPIT. 
This method was further enhanced by passing the non-retained protein fraction (first 
flow-through) through a second Con A column and then passing the second non-retained 
protein fraction (second flow-through)  through the third Con A column (3 sequential 
pull-downs) yielding 394 benchmark proteins. 
Glycoproteome of Toxoplasma gondii is not yet fully understood. However, 
evidence suggests that glycosylation could be essential for cyst formation and 
maintenance which is characteristic of chronic stage of disease. The focus of the second 
part of dissertation is to better understand the differences in glycoproteomes of 
tachizoites and tissue cysts. Cyst proteins pulled down using optimized sample 
preparation method that do not appear in the tachyzoites pulldowns could be critical 
elements in the structural stability of the tissue cyst.  
 
KEYWORDS: Mass spectrometry, glycoproteomics, lectin affinity purification, 
MuDPIT, Toxoplasma gondii. 
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CHAPTER 1 
STATEMENT OF RESEARCH 
 
 
Toxoplasma gondii is obligate intracellular protozoan parasite that causes the 
disease called toxoplasmosis.  This parasite undergoes three stages in its lifecycle.  In the 
primary host the parasite is in the stage of oocysts.  Shortly upon ingestion by the 
secondary host it transforms into rapidly growing tachyzoites causing the acute stage of 
toxoplasmosis.  Tachyzoites localize in skeletal muscle, myocardium, brain, and eyes and 
develop into slow growing bradyzoites contained in tissue cysts.  These cysts remain in 
the host throughout the life causing the chronic toxoplasmosis. 
The logical way to prevent the chronic toxoplasmosis is to prevent the cyst 
formation.  However, that mechanism of parasite’s transformation from the tachyzoite to 
bradyzoite form and the formation of tissue cysts is yet unknown.  According to current 
knowledge, there is a strong indication that the differences in protein glycosylation 
between tachyzoites and tissue cysts may provide a better insight into this process and, 
therefore, suggest the possible ways to prevent it.   
Estimates suggest that over 30% of global human population is infected and 
suffers from toxoplasmosis.  According to Centers for Disease Control and Prevention 
(CDC), the number of infected men, women and children in the USA only is around 60 
million.  Currently, only palliative care can be utilized but the cure is yet to be 
discovered.   
Despite such a wide spread infection that sparks scientific interest, this parasite’s 
weaknesses and, therefore, potential drug targets, remain largely unknown.  One of the 
reasons is the lack of methodologies to study the parasite.  This dissertation represents the 
efforts toward developing a method to study the glycoproteome of intracellular organisms 
and consequently increase the knowledge base of Toxoplasma gondii. 
The dissertation is organized in three main parts.  The first chapter outlines the 
current knowledge and background of only a relevant subset of methodologies applied in 
proteomics.  In addition to the definition of proteomics and bottom-up proteomics, the 
discussion focuses on separation methods as well as ionization techniques, mass 
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spectrometry and data analysis.  These methodologies provide valuable tools utilized to 
study the glycoproteome of Toxoplasma gondii.   
Second chapter describes the steps in developing the workflow to study the 
glycoproteome.  Methods are validated utilizing a whole cell lysate of HeLa cells as a 
benchmark.  The workflow is crafted by choosing the best approach for each step in the 
method. 
The established workflow developed in Chapter 2 is applied to study 
glycoproteomes of tachyzoite and cyst form of Toxoplasma gondii is discussed in the 
third chapter.  Analyzing the differences between the two proteomes provides the 
direction for further research that is beyond the scope of this dissertation. 
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CHAPTER 2 
INTRODUCTION 
 
 
Proteomics 
 
Proteomics is an ever-growing set of qualitative and quantitative methodologies 
used to define the structure and function of all proteins.  [1, 2]  Considering the role of 
proteins and their interactions in cellular function, proteomics has become a leading 
technology to further unravel biological processes.  [3] 
Various analytical disciplines contribute to proteomics but mass spectrometry 
became the method of choice for analysis of complex protein samples.  Three pillars of 
mass spectrometry based proteomics are protein separations science, mass spectrometry 
(MS) and bioinformatics.  [4]  
Protein separation science focuses on enrichment of a subset of proteome from a 
highly complex proteome using a diverse set of strategies such as depletion of highly 
abundant proteins and sample fractionation attempting to decrease sample complexity.  
These strategies contribute to the overall analysis by reducing competition for ionization 
and improving duty cycle thus extending dynamic range of proteins identified by mass 
spectrometry. 
Mass spectrometry allows for high throughput analysis of proteome but, 
moreover, it has the ability to acquire higher-order information such as protein 
localization, protein-protein interactions and protein post-translational modifications 
(PTM).  [5] 
High throughput mass spectrometry generates extensive amounts of data that 
would be impossible to analyze without bioinformatics tools.  Utilizing various software, 
organizing and analyzing overwhelming amounts of biological data becomes a swift task 
enabling substantial contribution to the knowledge base. 
Proteomics, as a large-scale study of proteins, can generally be divided in three 
categories: structural proteomics that analyzes protein structure, functional proteomics 
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that analyzes protein-protein interactions and expression profiling proteomics that 
analyzes the expression of proteins.   
The global analysis of expressed proteins can identify particular proteins affected 
by a certain treatment or disease thus helping in drug target or biomarker discovery.  This 
dissertation will focus on this category utilizing structural proteomics to explain the 
glycoproteome of Toxoplasma gondii as a model system. 
 
 
Proteomics vs genomics 
 
Genome refers to the genetic material of an organism including both genes and 
non-coding sequences of DNA and RNA.  Genome of a certain organism is the same 
throughout all the cells comprising that organism.  After transcription of DNA to RNA, 
proteins are expressed in the process called translation.  However, a large portion of the 
genome will be silenced until environmental stress or other extracellular signal stimulates 
the expression of a certain protein.  Therefore, regardless of technique, it will not be 
possible to visualize all proteins that genome can code for.  [6]  
While the genome is the same from cell to cell, the proteome is very different 
depending on the cell type and function.  Also, as a consequence to stimuli genes can 
alter protein expression or transform their function.  Therefore, information obtained 
from genome sequencing does not depict currently expressed proteome.   
Most proteins are posttranslationally modified that further contributes to 
complexity.  There are many types of posttranslational modifications (PTM) such as 
glycosylation, phosphorylation, acetylation, methylation and many other.  These 
modifications usually regulate protein function and make the whole proteome very 
complex and dynamic.  As the name suggests, PTMs take place after translation, and 
therefore, cannot be fully understood and studied at the genome level. 
However, genomics provided an enormous benefit to proteomics.  Those two 
technologies are complementary and some scientific questions are better addressed by 
one over the other approach.  [3]  Simply, the genome provides possibility while the 
proteome is your reality.   
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Genomics alone cannot determine the nature of functional proteins.  Hence, 
proteomics, as a study of the proteome, is necessary to analyze the current state of any 
organism, in health or disease, at molecular level.   
 
 
Proteomics Strategies 
 
Two major strategies used for protein identification are top-down and bottom-up 
proteomics.  The top-down approach analyzes intact proteins while bottom-up analyzes 
chemically or enzymatically produced peptides.  Even though the top-down strategy has 
better sequence coverage and characterization of posttranslational modifications, front-
end separation of intact proteins is arduous and it requires higher mass accuracy 
instruments.  The bottom-up approach is much more suitable for complex protein 
mixtures and large-scale analysis.  [1, 7] Therefore, bottom-up proteomics will be 
discussed in more details. 
Bottom-up proteomics is based on proteolytic digestion of proteins prior to mass 
analysis.  Among many available proteases trypsin is the most widely used for generating 
peptides for mass spectrometry analysis.  Trypsin is a serine protease that cuts the protein 
sequence on the C-terminal side of lysine and arginine unless they are followed by 
proline.  This results in peptides with at least two protonation sites, C-terminal basic 
residue and N-terminal amino group which is a minimum requirement for tandem mass 
spectrometry.  [4, 8-10] 
Tandem mass spectrometry is a multi-stage mass analysis that provides a unique 
capability to obtain structural information that can be useful in structure elucidation.  It is 
the key technique for protein or peptide sequencing and posttranslational modification 
analysis.  Collision-induced dissociation (CID) produces peptide fragments and provides 
information about peptide sequence.  Multiple collisions with gas atoms internally heat 
the peptide cations which results in peptide bond fragmentation.  However, this process 
also leads to losses of water, NH3, and labile posttranslational modifications as sulfation 
or nitration of tyrosine.  Consequently, sequence information of large peptides is limited.  
[5, 11] 
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The result of peptide sequence analysis is then searched against database of in 
silico generated peptide fragmentation patterns where algorithms are utilized to 
reconstruct the protein sequence.  However, there is an overwhelming number of 
proteolytic peptides in a sample, and only a small subset of all peptides in a sample can 
be analyzed in a single MS run.  Mass spectrometers only sample a small percentage of 
the total number of peptides in a sample which limits the number of proteins in a sample 
that can be identified.  [7] 
Overall, the bottom-up strategy, with good front-end separation is well suited for 
large scale protein identification and analysis of posttranslational modification, therefore, 
it is utilized in method development for glycoproteomics. 
 
 
Separation Technologies 
 
 
High Performance Liquid Chromatography (HPLC) 
 
Prof.  Csaba Horváth first mentioned the HPLC acronym in 1970 describing high 
pressure liquid chromatography where high pressure of maximum 500 psi was used to 
generate the flow required for liquid chromatography in packed columns.  Soon after, 
new pumps were developed with maximum pressure of up to 6,000 psi that together with 
improved injectors, detectors, and advanced packing material gave a new name to the old 
acronym, high performance liquid chromatography.  [12] 
Today HPLC is one of the most powerful tools in analytical chemistry with the 
ability to separate, identify, and quantify compounds that are present in any sample 
dissolved in a liquid.   
Components of HPLC system are: injector, pump, separation column and 
detector.  Appropriate mixture of solvents, mobile phase, is continuously running through 
the system under high pressure.  After injection the analyte, now within the mobile phase, 
is forced through the separation column.  Column is packed with the stationary phase 
comprised of small particles (3 – 10 µm) with specific residue that have different affinity 
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toward components of the passing analyte.  Considering the affinity of the residue, 
components of the analyte are separated by how long they are retained on the residue.  
The least retained components are eluted from the column first with the short retention 
time followed by strongly retained ones with the long retention time.  From the column 
the flow is directed toward the detector which in our case is mass spectrometer. 
The choice of liquid chromatography technique depends on the type of sample.  
Reversed-phase chromatography and ion exchange chromatography together with mass 
spectrometry analysis are typically used for peptide separation in proteomics. 
 
 
Reversed Phase (RP) Chromatography 
 
Reversed phase liquid chromatography (Figure 2.1) is based on interaction 
between the analyte within a polar mobile phase and hydrophobic stationary phase.  
Nonpolar stationary phases are often made of spherical silica particles with surface 
modified with hydrocarbon chains called the bonded phase.  Particles are made porous in 
order to increase their surface area and consequently the number of hydrocarbon chains 
that will bind the analyte. 
In highly polar (aqueous) mobile phase analytes bind to the stationary phase.  
Using organic solvent gradient, when the non-polarity of the mobile phase matches or 
exceeds non-polarity of the analyte, it will desorb from the stationary phase into the 
mobile phase.  Therefore, analytes are eluted in the order of increasing hydrophobicity.   
Analyte interacts with the stationary phase via weak van der Waals or dispersive 
interactions that are the result of overlap of the outer electron clouds between the analyte 
and stationary phase. 
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Figure 2.1. Principles of reversed-phase liquid chromatography.  A. Analyte bound to the 
stationary phase.  B. Analyte eluted from the stationary phase due to presence of organic 
solvent. 
 
Mechanism of the analyte transfer from the mobile phase to or from the stationary 
phase can be explained by adsorption and desorption of the analyte from the stationary 
phase.  In both cases, transfer of the analyte is explained by equilibrium process of the 
environment exchange, from mobile phase to stationary phase and back to mobile phase, 
as described by the equation.  The stage when the equilibrium has been established is 
called theoretical plate height.  [13, 14] 
 Astationary phase  ↔  Amobile phase 
 
Stationary phase is packed in the column.  Properties of chromatographic column 
such as retention time, resolution and selectivity depend upon particle size, pore size, 
functionality and chain length of the bonded phase and column length.  They also depend 
on mobile phase composition, gradient profile as well as the length and internal diameter 
of connecting tubing.  Resolution equation explains the relationship between retention 
(k), efficiency (N), and selectivity (α): 
 Rs =  14 N1/2 (α − 1α )( kk − 1) 
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While the smaller particle size improve efficiency (N), retention (k) depend on 
duration of the whole analysis.  However, selectivity has the greatest impact on 
resolution.  Selectivity can be explained as the distance between adjacent peaks and it 
increases with increasing distance. 
Column efficiency is determined by the plate count (N) and the theoretical plate 
height (H). N =  LH 
 
L − length of the separation column 
H − theoretical plate height 
 
Van Deemter equation describes the relationship between the theoretical plate 
height and linear velocity. 
 H = A +  Bu + Cu 
 
u − linear velocity of the mobile phase 
A − Eddy diffusion 
B − longitudinal diffusion coefficient 
C − resistance to mass transfer in the stationary (Cs) and mobile (Cm) phases 
 
Eddy diffusion term (A) describes different paths analyte can have while passing 
through the column and it depends on the size of particles and their uniformity.   
Longitudinal diffusion term (B/u) depends on molecular diffusion in the axial 
direction.  Cu describes the mass transfer time needed to establish the equilibrium 
between mobile and stationary phase. 
The column efficiency increases with lower value of theoretical plate height.  
Higher values of theoretical plate height indicated longer time to establish the equilibrium 
and, therefore, broader chromatographic peaks.  [15] 
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Liquid Chromatography – Mass Spectrometry (LC-MS) for peptides 
 
Peptides and proteins are usually analyzed by reversed-phase HPLC with mass 
spectrometric detection.  Specificity and selectivity of mass spectrometry lower 
requirements for separation selectivity but put constrains on method development by 
limiting the number of workable reagents. 
HPLC delivers the analyte in the liquid form but mass spectrometers analyze ions 
in the gas phase.  One of techniques that can bridge the gap and transfer peptides to the 
gas phase without degradation is electrospray ionization (ESI).  This technique is affected 
by the surface charge and tension, the size of the liquid drop delivered from the HPLC 
system, solvent volatility and solvation strength.  In turn, these parameters are affected by 
the internal diameter and the length of the column and the post-column tubing, mobile 
phase composition, pH, modifiers, etc.  [16] 
Concentration of the analyte reaching ESI at the certain moment depends on the 
internal diameter of the HPLC column.  Analytes are less diluted in columns with smaller 
diameter thus yielding higher signal on the detector.  Typical internal diameters are 
between 180 and 360 µm for flow rates of 1 to 10 µL/min. 
However, after the analyte exits the separation column it passes through the 
connecting tubing until it reaches the ESI probe.  During that time dispersion of the 
analyte occurs leading to the peak broadening and decreased sensitivity.  For that reason 
the post-column tubing should be minimized. 
Composition and properties of the mobile phase have a major impact on 
ionization efficiency.  The usual composition of the mobile phase for HPLC systems with 
mass spectrometry detection is a mix of water and organic modifier, such as methanol or 
acetonitrile, as well as ionic modifier as formic acid (pKa = 3.77) that is a preferred ionic 
modifier for LC-MS systems.  Ionic modifier is added to reversed-phase HPLC as an ion 
pairing agent that increases retention time, prevents ionization of carboxyl groups and 
protonates amine and silanol groups.  [13, 17] 
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The purpose of the organic modifier is to compete for the analyte against the 
stationary phase.  Most commonly used organic modifier is acetonitrile due to lower 
surface tension of the mixture resulting in better electrospray ionization. 
Peptides can carry one or more charges, on carboxylate (-COOH) and amine (-
NH2) groups as well as on amino acid residues.  Number of charges depends on the pH of 
the mobile phase and pKa value of each residue.   
 
 
Strong Cation Exchange Chromatography 
 
As stated before, peptides can carry one or more charges, on carboxylate (-
COOH) and amine (-NH2) groups as well as on amino acid residues.  The overall charge 
of the peptide depends on its amino acid sequence.  Ion exchange chromatography 
separates peptide on the type of their overall charge (positive or negative) and on the 
relative charge strength. 
The premise of ion exchange chromatography is that ions can be exchanged with 
ions of the same type regardless of their mass.  Ions from the solution reversibly bind to 
ions of the opposite charge that are bound to the stationary phase called ion exchanger.  
Desorption of the analyte depends upon ionic strength of the mobile phase.  Analytes 
with higher net charge require higher ionic strength to desorb.  [18] 
Ion exchange stationary phases are classified in two main groups: cation (separate 
cations) and anion (separate anions) exchangers.  Cation exchangers utilize acidic groups.  
If those groups are derived from the strong acid such as sulfonic acid, they are called 
strong cation exchangers.  [4] 
One of the factors affecting the elution is exchange capacity, or the concentration 
of ion exchange groups on the surface of the particle.   
Another factor to consider is the pH of the mobile phase.  The analyte will not be 
retained on the column unless it is ionized at the particular pH.  Also, if the ion exchanger 
is neutralized that site is no longer available for binding. 
The nature and concentration of the salt controls its eluting strength.  NH4+ is 
commonly used in strong cation exchange chromatography. 
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The separation of components of complex mixtures is achieved by utilizing salt 
gradients that gradually increase ionic strength of the mobile phase thus eluting 
components in the order of increasing net charge (Figure 2.2).  [4, 18] 
 
 
Figure 2.2.  Principles of the strong cation exchange liquid chromatography.  A. Analyte 
bound to the stationary phase.  B. Analyte eluted from the stationary phase due to 
presence of ions in the solution. 
 
 
Multidimensional Protein Identification Technology (MuDPIT) 
 
Regardless of the species, the whole cell lysate contains thousands of proteins.  
This complex mixture is further complicated utilizing digestion to produce peptides 
required for mass spectrometric analysis.   
On the other hand, mass spectrometry can analyze a limited number of peptides at 
any given moment.  Additionally, limited duty cycle of mass spectrometers may result in 
undersampling of complex proteomic samples.  Low abundant peptides are at higher risk 
of being lost considering that only three most abundant peptides undergo fragmentation.   
For all these reasons, complex samples like whole cell lysate have to be separated 
in multiple less complex samples before mass spectrometric analysis to increase the 
resolution and peak capacity that are crucial to the success of the analysis. 
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Solution lies in the reduction of sample complexity which is achieved by sample 
purification and fractionation.  If the experiment aims to study a subset of proteins, the 
complexity of the sample can be attained by removal of high abundance proteins 
utilizing, for example, affinity chromatography.  Fractionation of the sample based on a 
certain physico-chemical property and performing multiple HPLC runs further decreases 
sample complexity and reduces the number of coeluting peptides.   
The most commonly used fractionation method is multidimensional protein 
identification technique (MuDPIT).  The strength of this method lies in combination of 
two orthogonal types of separation (Figure 2.3).  First, peptides are separated based on 
differences in their accessible surface charges utilizing strong cation exchange (SCX) 
chromatography.  Peptides in each subgroup are then separated based on differences in 
their hydrophobicity utilizing reversed-phase HPLC chromatography.[19] 
For MuDPIT analysis strong cation exchange resin is packed in tandem to 
reversed-phase C18 resin.  Separation starts when strong cation exchange resin binds 
positively charged peptides.  Peptides are eluted off the strong cation exchange column 
by increasing ionic strength of the mobile phase in a stepwise manner from low to high 
salt concentration.  A portion of peptides is released in each salt step depending on the 
salt concentration.  Those peptides proceed to reversed-phase C18 where they bind based 
on their hydrophobicity.  Using organic gradient, peptides are eluted off the C18 resin and 
continue toward the mass spectrometer.  Once the C18 resin is equilibrated back to high 
aqueous conditions, the next cycle starts with the higher salt concentration.  [20-23] 
This method is customizable in terms that complexity of the sample dictates the 
number of the salt steps and the slope of the organic gradient. 
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Figure 2.3.  A. Finnigan LCQ Deca ion trap mass spectrometer coupled with LC 
Packings Ultimate 47 quaternary capillary LC system.  B. Strong cation exchange and 
reversed-phase C18 columns in series. 
 
Separation can be done online as well as offline.  In offline version, elutions from 
strong cation exchange resin are collected and then injected separately.  However, the 
online version prevents sample loss rendering increased sensitivity and greater dynamic 
range of MuDPIT analysis than some other methods, such as an offline ion exchange 
approach. 
However, regardless of how well is the sample separated or purified there will 
always be a portion of the proteome such as low-abundant proteins, proteins with extreme 
15 
 
pI and molecular weight and membrane proteins that will be lost during sample 
processing.  [22][23] 
 
 
Electrospray Ionization - Ion Trap Mass Spectrometry 
 
Peptides are polar, nonvolatile and thermally unstable species that are eluted from 
the liquid chromatography system in the solution, and hence incompatible with the mass 
spectrometry analysis, that requires ions in the gas phase.  At first glance, mass 
spectrometers would not be as suitable detectors for HPLC technique as they are for gas 
chromatography.  However, an appropriate sample introduction technique can bridge the 
gap.  One of techniques that transfers peptides to the gas phase without degradation is 
electrospray ionization (ESI) particularly useful for the analysis of polar compounds.  
[24, 25] 
 
 
Electrospray ionization (ESI) – Making Droplets 
 
Analyte is eluted from the HPLC column in a liquid mobile phase and must be 
converted into gas phase ions that can then be analyzed by the mass spectrometer.  
Ionization of the analyte occurs in the solution within the charged mobile phase and the 
next challenge is how to transfer it to the gas phase.  Electrospray ionization (ESI) is 
particularly popular because the process of gas-phase ion formation takes place at the 
atmospheric pressure and allows ion formation directly from the solution.  Since peptides 
are not fragmented during this process ESI is considered to be a “soft ionization” 
technique.  This technique primarily generates molecular ions (M+), protonated molecules 
([M + H]+), simple adduct ions ([M + Na]+) and ions with neutral losses ([M + H – 
H2O]+). 
The electrospray ionization process occurs at the ESI probe whose purpose is to 
produce charged aerosol droplets that contain sample ions.  The whole process involves 
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three steps: 1) nebulization of sample droplets into smaller charged droplets, 2) 
desolvation of droplets and 3) ion ejection. 
 
 
Figure 2.4. ESI chamber, Finnigan LCQ Deca ion trap mass spectrometer. 
 
HPLC column is directly attached to ESI probe (Figure 2.4).  The sample is fed in 
to a fused silica capillary that is, together with spray needle and spray nozzle, part of the 
ESI probe.  High positive voltage (+500 V to +4.5 kV) applied to the tip of the spray 
needle induces charge separation within the drop by pulling positive charge towards the 
liquid front and forming the Taylor cone.  Negative charge is removed by discharge 
against the metal wall of the spray needle.  [26] A small highly positively charged droplet 
leaves the surface of the liquid when electrostatic repulsion overcomes surface tension.  
Opposite from the ESI probe is a heated capillary.  Potential between the spray needle 
and heated capillary drives the droplet through the surrounding gas toward the entrance to 
mass analyzer through ion optics.  Assisted by nitrogen gas, applied through the spray 
nozzle, solvent molecules leave the droplet that in turn decreases in size.  According to 
ion evaporation model (IEM) the charge density at the droplet surface increases until it 
reaches about 80% of the Rayleigh limit when electrostatic repulsion becomes stronger 
than the surface tension and the droplet undergoes Coulomb explosion into smaller 
droplets.  [27-30]  This process continues until droplets are so small that ions desorb into 
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the gas phase and are sampled by the mass analyzer.  After ejection and before they reach 
the mass analyzer, ions can undergo some gas-phase reactions like proton transfer and 
charge exchange.  [31] 
Several features affect the ESI process like solvent volatility, droplet size and 
liquid surface tension.  Smaller droplets are formed with lower flow rates which is 
achieved with splitter. Another factor influencing qualitative and quantitative 
performance of mass spectrometer is variability of analyte response known as ion 
suppression.  The main cause of this process is presence of less volatile compounds in a 
solution phase that can change the droplet solution properties.  But other processes as 
precipitation and ion pairing can also be responsible for ion suppression.  All these in turn 
affect the droplet formation and evaporation thus affecting the amount of charged ions 
reaching the detector.  [17, 32] 
Also, pH of the mobile phase should be chosen so it keeps the analyte charged.  
Mobile phases with low pH are utilized for the analysis of basic analytes in the positive 
electrospray mode.  Weak acid, like formic, is added to adjust the pH while salts, strong 
acids and bases are very detrimental due to solid deposits.  The concentration of the 
added acid should be low to avoid the competition with the analyte for the proton because 
that can also decrease analyte response.  [33] 
 
 
The Path of Ion 
 
Droplets created in ESI process travel toward the heated capillary that further 
helps desolvation process.  Temperature of the heated capillary can be anywhere from 
120 °C to 350 °C depending on the flow rate, type of the analyte and the mobile phase.  
Positive ions are transported through the heated capillary utilizing pressure gradient from 
the atmospheric region to capillary-skimmer region (~ 1 torr) assisted by a potential of 0 
to +10 V and enter the tube lens.  The purpose of the tube lens is to focus ions and stop 
the flow of ions into the mass analyzer during detection.  Potential applied to the tube 
lens focuses ions toward the opening of the skimmer.  Tube lens offset voltage is 
additional potential (0 to +40 V) applied during ion collection that accelerates ions that 
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collide with the background gas further helping with desolvation process and thus 
increasing sensitivity.  However, if collisions are too energetic sensitivity decreases due 
to fragmentation (ion source collision induced dissociation).  Tuning procedure optimizes 
sensitivity of the tube lens offset voltage.  During detection of ions that already entered 
mass analyzer, the voltage applied to the tube lens is -200 V thus deflecting all positive 
ions away from the opening of the analyzer.  [33] 
Passing the skimmer, ions enter lower pressure ion optics region at 10-3 torr on 
their way to mass analyzer.  Ion optics have three parts: quadrupole, octapole and 
interoctapole lens.  Electric field made of RF (2.45 MHz, 400 V) and dc offset voltage (-
10 to +10 V) applied in this region guides and focuses ions that are now entering the 
vacuum region of the mass analyzer.  [33] 
 
 
Figure 2.5. Electrospray ionization (ESI) process. 
 
 
Mass Analyzer - Ion Trap 
 
The heart of every mass spectrometer is mass analyzer where ions are separated 
based on their mass to charge ratios (m/z) and sent to the detector.  There are four general 
types of mass analyzers: quadrupole, time of flight, sector and ion trap.  Our instrument is 
equipped with ion trap that will be the focus of further discussion. 
An ion trap consists of three stainless steel electrodes, two end-caps and one ring 
electrode, of hyperbolical geometry (Figure 2.6).  They together form the cavity with 
dimensions of r0 and z0 as shown in the picture.  Both end caps have holes in their centers 
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where ions enter the cavity of the ion trap and exit through the opposite end cap after they 
have been separated according to their mass to charge ratio.  [31] 
 
 
Figure 2.6.  Ion trap elements: two end-caps and one ring electrode. 
 
As the name says, an ion trap mass analyzer traps ions in a three dimensional 
electric field.  Ions are stored, separated according to their mass to charge ratio and then 
selectively ejected which increases the sensitivity of the device.  [34]  
Gating lens controls the entry of the ions into the trap.  Negative potential is 
applied to it to enable positive ions to enter the trap.  The time of ion accumulation is 
optimized to allow for maximal signal and minimal space charge.  Excess ions in the trap 
are detrimental due to changes in electrical fields they cause, while too few ions lead to 
loss of sensitivity.  Once the optimal amount of ions entered the trap the potential on the 
gating lens is changed to positive to prevent further entrance of positive ions.  Ion trap 
can analyze negative ions as well.  In that case the potential applied to the gating lens is 
reversed.  [35] 
Inside the ion trap RF oscillating potential is applied to the ring electrode and 
focuses ions to the center of the trap.  Ions move in complex pattern and high kinetic 
energy.  Damping gas (helium, 1 mTorr) is used to prevent the premature ejection by 
colliding with the ions and reducing their kinetic energy.  This results in focusing ions 
toward the center of the trap.  [33, 35] 
Potential applied to the ions in the ion trap is described by the following equation: 
 
Φr,z  =  ( U − V cosΩt)2  �r2 − 2z2r02 � +  ( U − V cosΩt)2  
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U – dc potential 
V – Rf amplitude applied to ring electrode 
Ω − angular frequency of RF (V), typically 1.1 MHz 
r0 – internal radius the ring electrode 
r – distance between the ion and the ring electrode 
z – distance between the ion and the end-cap electrode 
 
Solutions are given by the second order differential equation named the Mathieu 
equation.  Ion stability in the ion trap is described with two dimensionless Mathieu 
parameters az and qz, 
 qz =  2eVmr02Ω2 
 az =  4eUmr02Ω2 
 
Dimensions of the ion trap, angular frequency of RF potential, mass and charge of 
the ions are constant values.  Therefore, dc potential (U) and RF amplitude (V) control 
ion’s motion described by the solutions of Mathieu’s equation or graphically presented 
with the plot of az vs.  qz named Mathieu stability diagram (Figure 2.7).  [36] There are 
two types of solutions of Mathieu’s equation:  
a) Periodic and unstable – describe  boundaries of unstable region of 
the stability diagram, 
b) Periodic and stable – describe motion of ions within the ion trap. 
 
Ions are trapped if the intersection of az and qz falls within boundaries of the 
stability diagram.  However, if the intersection value falls outside of boundaries of the 
stability diagram, the ion is ejected.   
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Figure 2.7.  Mathieu stability diagram for a 3D quadrupole ion trap 
 
In commercial ion traps dc voltage is constant and set to give radial stability to all 
ions.  Their stability and ejection is controlled in the axial direction. 
When dc voltage is set to zero stability diagram collapses to qz axis and ion trap 
operates in the “mass selective instability scan” mode.  Rising RF potential applied to the 
ring electrode moves the ions along the qz axis.  Stable ion trajectories have the qz value 
between 0 and 0.908.  As the qz value approaches 0.908, ions gain the kinetic energy, 
reach the boundary of the stability diagram, become unstable and are ejected from the ion 
trap through holes in the end-cap.  This is the low-mass cutoff limit.  Mass selective 
instability scan mode of operation generates the full scan mass spectrum by sequentially 
ejecting ions from low m/z to high m/z.  [31, 35] However, this approach does not allow 
the selection of ions. 
Resonance ejection is one of the methods for ion selection that induces instability 
of a particular ion utilizing ac voltage of high amplitude or supplementary RF potential 
on the end-caps that changes secular frequency of the ion resulting in its ejection. 
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An alternative method is axial modulation where RF frequency is constant but the 
amplitude is ramped which can selectively eject several or all ions. 
After ejection, ions are accelerated by the conversion dynode and sent to the 
channel electron multiplier for detection.  [31] The number of ions reaching the detector 
depend on ESI efficiency, ion sampling efficiency into the vacuum and ion transmission 
efficiency through ion optics and the ion trap.  [27] 
 
 
Tandem Mass Spectrometry 
 
Tandem mass spectrometry (MS/MS) is a multiple stage mass spectrometry that 
acquires data in a data dependent mode.  One of the advantages of an ion trap mass 
analyzer is the ability to perform tandem mass spectrometry in time without the need for 
an additional mass analyzer. 
The first step in data-dependent mode is to acquire a full scan mass spectra.  
When one of the ions reaches signal threshold, it is isolated by applying the appropriate 
RF wave form that will eject all other ions.  Then, “tickle” potential is applied across the 
end-caps to resonantly excite the ion of interest.  This is similar to axial modulation.  
However, the amplitude of “tickle” potential is chosen in such manner not to eject the ion 
but to pull it away from the center of the trap.  Ion gains energy from the RF drive 
potential and collides with helium experiencing collision induced dissociation (CID).  
Resulting fragments are analyzed by increasing amplitude of RF potential and ejected 
from low m/z to high m/z.  After obtaining the MS/MS spectrum analyzed ion is put on 
the exclusion list and not analyzed during selected time frame regardless of the signal 
intensity.  During that time the ion trap fills again with all ions and instrument analyzes 
other ions that reached signal threshold. 
To enhance the statistics three micro-scans are averaged to generate the data 
dependent full scan spectrum.  Three most intense ions are then subjected to tandem mass 
spectrometry with five spectra averaged to produce one MS/MS spectrum.   
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Bioinformatics for Proteomics 
 
CID of the peptide cleaves the amide bond and generates fragments characteristic 
of the specific amino acid sequence (Figure 2.8).  Charge can be retained on N-terminus 
yielding a, b and c ions or on C-terminus yielding x, y and z.[37]  However, b and y ions 
are most abundant when low energy CID is employed. 
 
 
Figure 2.8.  Peptide fragmentation notation. 
 
The first step in proteomic data processing is to assign the spectrum of a fragment 
to a primary protein sequence.  To accomplish that an overwhelming number of 
computational approaches and tools have been developed.  [38]  In general, experimental 
mass values are compared with calculated peptide masses and fragment ion mass values.  
Calculated masses are obtained when the set of cleavage rules is applied to the protein 
primary sequence database.  Scoring algorithms are used to identify the closest matches 
thus identifying the unknown protein from the sample.  Considering proteomes of 
different species are not yet fully elucidated if the sequence database does not contain the 
unknown protein then the algorithm matches it to the protein of the closest homology.  
[39] 
Mascot is a powerful search engine that provides search method for MS/MS ion 
search, and therefore, is utilized for the purpose of qualitative proteomics.   
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Mascot search engine converts MS/MS spectra into mascot generic format 
(MGF), which is a list of pairs of mass and intensity values.  MGF files are searched 
against the database of calculated peptide or fragment ion masses.  [40] 
A set of search parameters, such as choice of proteolytic enzyme, number of 
missed cleavages, peptide mass tolerance, choice of search masses and protein molecular 
weight, provide versatility and the ability to identify proteins with maximum 
discrimination and the highest score.   
Mascot search engine is based on Mowse algorithm but it also adds probability-
based algorithm.  [41]  Proteins are identified based on the probability (P) that the match 
between the experimental data and theoretical value is a random event giving the lowest 
probability to the best match.  The score is calculated using the equation below. 
  score =  −10 ×  log10 P 
 
These values are converted into Mowse scores assigning the highest score to the 
best match.  [42] 
Mowse (MOlecular Weight SEarch) method identifies the proteins based on 
molecular weight of their respective peptides measured by mass spectrometry.  To 
achieve that, experimental data are first compared with calculated peptide masses in the 
sequence database and only entries that fall within a given mass tolerance are accepted as 
a match.  Each match is assigned a statistical weight that is determined utilizing empirical 
factors such as frequency (F).   
A frequency is calculated using matrices where intervals of 100 Da of peptide 
mass were put in the rows (i) and intervals of 10 kDa of intact protein mass were put in 
columns (j).  Each experimentally obtained ion falls into the appropriate matrix element 
fi,j. The frequency of occurrence gives the size distribution of peptide masses as a 
function of protein mass.  The frequency is normalized by dividing the elements of each 
10 kDa column by the largest value in that column.  This process gives the factor m 
according to the equation below. 
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mi,j =  fi,jfi,jmax in column j 
 
Factors m for each entry are then multiplied (∏ mi,jn ) and used together with the 
molecular weight of the entry (MWprot) to calculate the score utilizing the following 
equation score =  50,000MWprot  × ∏ mi,jn  
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CHAPTER 3 
SAMPLE PREPARATION FOR MASS SPECTROMETRY OF GLYCOPROTEINS 
 
Following translation, the next step in protein biosynthesis are various 
posttranslational modifications (PTM) such as glycosylation, methylation, 
phosphorylation and many others.  Considering the critical role of PTMs as regulators of 
protein activity and function it is essential to expand the current body of knowledge on 
this topic.  However, very low levels of PTMs within complex biological system poses an 
impediment to researchers.  Therefore, development of new enrichment techniques are 
necessary to prevail in this challenge. 
The purpose of this chapter of dissertation is to describe the effort put to develop 
the new technique for enrichment of glycoproteins from the complex matrix such as 
whole cell lysate. 
 
 
Posttranslational modifications of proteins 
 
Posttranslational modifications (PTM) are ubiquitous and denote the attachment 
of various functional groups or structural changes of the proteins after translation further 
diversifying protein structure beyond what is acquired by gene transcription.  These 
modifications play a key role in many biological events like gene expression, signal 
transduction, protein-protein interaction and many more because they regulate protein 
activity by changing its surface or introducing new functional groups.  In turn, this 
changes thermodynamic and kinetic features of proteins as folding rate and stability.  [43, 
44] 
There are many PTMs such as glycosylation, phosphorylation, methylation, 
ubiquitination, lipidation, nitrosylation, acetylation and proteolysis.  Glycosylation has 
been recognized as one of the major PTMs.  [44]  Since glycoproteins are the central 
theme of this dissertation glycosylation is discussed in more details.   
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Protein Glycosylation 
 
In general, glycosylation is the process of covalent binding of glycans and 
proteins catalyzed by a series of enzymes.  Glycosylation can be discussed from the 
perspective of protein or of glycan.  From the protein perspective, benefits of 
glycosylation are enhanced thermal stability and folding kinetics of the protein, increased 
solubility and resistance to proteolysis.  Also, the process of glycosylation itself depends 
on the number, location and surroundings of the glycosylation sites on the protein.  [45] 
From the glycan perspective, properties of the protein depend on the size of the glycan, 
its flexibility and structure.  [43, 45] 
The formation of the bond between a saccharide and the amino acid is the first 
step in biosynthesis of glycan parts of glycoproteins.  This bond initiates a series of 
enzymatic steps that yield an elaborate oligosaccharide structures on the protein.  It is 
known up today that 13 monosaccharides and 8 amino acids are involved in at least 41 
glycoprotein linkages divided in the following five types of glycosylation:  
1. O-linked glycosylation – through hydroxyl oxygen of serine, threonine or 
tyrosine, 
2. N-linked glycosylation – through nitrogen of asparagine side chain if in the 
sequence N-X-(S/T) as standard consensus sequence or N-X-C, N-G and N-X-V 
as non-standard consensus sequences, where X cannot be proline,   
3. C-linked mannosylation – mannose linked to the tryptophan side chain if in the 
W-X-X-W consensus sequence,  
4. glypiation – through glycosylphosphatidylinositol (GPI) anchor that links proteins 
and lipids. 
5. phosphoglycosylation – mannose, fucose, xylose or N-acetyl-D-glucosamine 
linked to serine.  [46] 
 
Sites of glycosylation vary throughout the cell and include Golgi complex, 
endoplasmatic reticulum, nucleus and cytosol.  [47]  However, the most abundant 
glycosylations in eukaryotic proteins are N-linked and O-linked protein glycosylations 
and they take place in cytoplasm, endoplasmic reticulum (ER) and the Golgi complex.   
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Large part of the proteome of the cell is synthesized and folded in endoplasmatic 
reticulum (ER) and then transported to the Golgi complex following a conventional ER–
Golgi secretory route.  One of the key functions of the ER is production of glycans.  
Mannose rich glycans are synthesized on the cytosolic face of the ER.  These precursors 
are then moved into the lumen of ER where they are further branched by adding more 
mannose and glucose.  While within ER precursor glycans are transferred to the 
asparagine residue onto still unfolded protein by glycosyltransferases thus forming N-
linked precursor glycans.  Once they reach Golgi complex, glycans are edited by 
glycosidases to form mature N-linked glycans.  O-linked glycosylation happens during 
passage through the Golgi complex.  [44, 48-52] 
After translation, newly synthetized proteins are transported from endoplasmatic 
reticulum to Golgi complex.  Along this path they are modified by the attachment of 
variety of different functional groups such as carbohydrates and lipids.  These groups 
change the structure and properties of proteins reversibly or irreversibly.  [44, 47] 
Golgi complex and endoplasmatic reticulum are not the only places where 
posttranslational modifications happen, however, those are sites of glycosylation.   
 
 
Glycans 
 
According to the IUPAC Gold book, glycans are defined as "compounds 
consisting of a large number of monosaccharides linked glycosidically".  [53] 
Glycosidic bond is the bond between the hemiacetal group of the saccharide and 
hydroxyl or amine group of another organic molecule (Figure 3.1). 
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Figure 3.1.  Example of α-glycosidic bond. 
 
Glycans are built from 9 different monosaccharides joined together with 
glycosidic bond to form oligosaccharides (2 – 20 monosaccharides) or polysaccharides 
(20 < monosaccharides).   Structures of polysaccharides are more complex than proteins 
since they can form various topologies.  They contribute to protein diversity not only 
between different organisms but different glycans can also be present on one type of the 
protein.  Even microheterogenious glycans that differ in the structure of only one or more 
of its monosaccharides can greatly alter thermodynamic properties of a certain protein.  
[54] 
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Table 3.1.  Glycan building monosaccharides. 
 
Monosaccharide 
Haworth 
projection 
 
Abbreviation 
 
Symbol 
 
D-glucose  
 
Glc 
 
       
 
D-Glucuronic acid  
 
GlcA 
 
       
 
D-Xylose  
 
Xyl 
 
       
 
L-Fucose  
 
Fuc 
 
       
 
N-acetylneuraminic acid  
 
            NeuAc 
 
       
 
D-Mannose  
 
Man 
 
       
 
D-Galactose  
 
Gal 
 
       
 
N-acetyl-D-glucosamine 
 
 
GlcNAc 
 
       
 
N-acetyl-D-galactosamine 
 
 
GalNAc 
 
       
 
 
Both N- and O- linkages are through N-acetylglucosamine.  However, N-linked 
glycans are bonded to asparagine, while O-linked glycans to serine or threonine.  Unlike 
O-linked glycans, N-linked glycans have standard and non-standard consensus sequence.  
The standard consensus sequence involves three amino acids.  It starts with asparagine 
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linked to any amino acid but proline and ends with serine or threonine (N–X–(S/T)).  
Additionally, there are two non-standard consensus sequences: asparagine – X – cysteine 
(N–X–C) and asparagine – X – valine (N–X–V) where X cannot be proline also.  [46] 
 
 
Figure 3.2.  The core sequence of N-linked glycans. 
 
All N-linked glycans have the same core sequence as shown in the (Figure 3.2).  
They are divided into three classes according to the monosaccharides attached to the core 
structure: 
1. Oligomannose – only mannose residues attached, 
2. Complex – each branch starts with N-acetylglucosamine (GlcNAc) and develops 
further, 
3. Hybrid – only mannose residues are attached to one of the core’s branches and the 
variety of monosaccharides on the other.  [55] 
 
O-linked glycans are covalently attached to hydroxyl group of serine or threonine 
by an O-glycosidic bond.  There are several types of O-linked glycans: 
1. O-N-acetylgalactosamine (O-GalNAc) – starts with N-acetylgalactosamine 
followed by galactose, N-acetylglucosamine, fucose, or sialic acid, but not 
mannose, glucose, or xylose, 
2. O-fucose – that can be elongated to a tetrasaccharide, 
3. O-glucose – typically exists as trisaccharide comprised of glucose and two 
xyloses, although it is also found as a monosaccharide, 
4. O-N-acetylglucosamine (O-GlcNAc) – starts with N-acetylglucosamine, 
5. O-mannose – very complex structures and common to both prokaryotes and 
eukaryotes.  [56] 
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Lectins 
 
Lectins are saccharide binding proteins ubiquitous across all species.  They also 
may have saccharides on their surface, which classifies them as glycoproteins, but what 
defines them as lectins is their ability to bind saccharides.   
Lectins’ major role is to facilitate cell to cell contact.  This contact is provided by 
interaction of lectin displayed on the surface of one cell with saccharide displayed on the 
surface of another cell.  A molecule of lectin usually has more than one saccharide 
binding sites.  Each site forms a weak bond with the saccharide, however, synergistic 
effect of multiple binding sites provides a strong interaction.  [51] 
There are two types of interactions between lectin and saccharide.  First type is 
when lectin with two binding sites binds two ligands.  These complexes are linear and 
flexible and ligands can vary in structure.  The second type is formed when either lectin 
or ligand has more than two binding sites yielding complex, cross-linked structures.  The 
ligand composition in this case has to be the same to be able to form the lattice.  [30, 57-
59] 
Lectins can be used for the purpose of studying the glycoproteome for substantial 
reduction of the sample complexity.  They are utilized for the extraction of glycoproteins 
from the whole cell lysate for the affinity chromatography technique. 
Concanavalin A (Con A) is one of the most widely used lectins.  Perhaps one of 
the reasons is its low affinity toward non-glycosylated proteins.   
Con A was used for the development and conformation of the method described 
in this dissertation to extract glycoproteins from the whole cell lysate of HeLa cells 
(benchmark) as well as from whole cell lysate of tachyzoites and tissue cysts of 
Toxoplasma gondii.  For that reason Con A is discussed in more details.   
 
 
Concanavalin A (Con A) 
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Concanavalin A (Con A) is a lectin isolated from jack bean Canavalia ensiformis.  
At pH 7.5 Con A is a tetramer but at the pH 5 and lower it reversibly dissociates in to 
dimers.  Each subunit is comprised of 237 amino acids and has a molecular weight of 26 
kDa.  They fold in the formation of two β sheets that create β sandwich.  [60] 
Also, each subunit has one saccharide binding site and two metal binding sites: 
one for a transition metal ion and one for calcium ion.  If metal ions are removed in 
acidic conditions Con A can no longer bind saccharides.  However, replenishing metal 
ions at the pH 7 restores saccharide-binding activity.  This proves that the role of metal 
ions is to pull the amino acid residues into proper conformation required for binding.  
[61-63] 
ConA binds α-mannose and α-glucose sugars and N-glycans but it does not bind 
O-glycans on animal cell glycoproteins.  The binding affinity is much higher for 
oligomannose-type N-glycans than complex-type biantennary N-glycans, while it does 
not bind highly branched complex-type N-glycans.   Examples of glycans that Con A 
binds are shown in the Figure 3.3.   Circled portions of glycans are required for binding.  
[64] 
 
 
Figure 3.3.  Example of glycans that Con A binds.  The parts of the glycan required for 
binding are in the box. 
 
Once Con A binds a glycan and after the purification procedure, it is important to 
select a competitive inhibitor that will provide elution of the glycoproteins.  Therefore, it 
is important to understand the mechanism of binding. 
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Con A binds the saccharide by forming hydrogen bonds with almost all hydroxyl 
groups on the saccharide.  The strongest bond is formed with D-mannose, then D-
fructose and lastly D-glucose which still contains at least a part of configuration required 
for binding.   
Con A binds the saccharide in the chair conformation with C4 deepest in the 
binding site and C1 closest to the surface.  Hydroxyl group on C1 is extending into the 
solvent and is not essential for binding with the protein, while the one on C2 has some 
influence on binding which is proved by the higher affinity of binding of D-mannose than 
D-glucose.  It seems that in D-mannose C2 hydroxyl group better approaches the surface 
of the protein.  However, hydroxyl groups on C3, C4 and C6 stabilize the conformation 
through hydrogen bonding with the protein and are essential for binding.   
The type of the bond and the substituents also play a role in the binding affinity.  
Con A has much higher affinity for α glycosidic bond than β glycosidic bond.  
Additionally, substituting hydrogen for the methyl group in α-methyl glycosidic bond 
increases affinity several fold.  As a consequence, methyl-α-D-mannopyranoside is the 
best binding inhibitor than any other saccharide, followed by methyl-α-D-
glycopyranoside (Figure 3.4).  [30, 64] 
 
Figure 3.4.  A. D-mannose, B. D-glucose, C. methyl-α-D-mannoside and D. methyl-α-D-
glycoside, Haworth projection. 
 
For the purpose of this project we utilized Con A for the separation of 
glycoproteins from the whole cell lysis.   
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Lectin Affinity Chromatography 
 
Affinity chromatography is based on specific interaction between ligand 
chemically bound to the solid support and the target molecule that is most often a 
biological molecule (Figure 3.5).  Therefore, molecules are separated based on their 
biospecific binding to the immobilized ligand.  The principle of affinity chromatography 
is shown in the figure below.   
 
 
Figure 3.5.  Affinity chromatography principle.  A.  Ligand binds the glycoprotein.  B.  
Elution of the glycoprotein utilizing saccharide as a competing ligand. 
 
 Fundamental principles of binding are based on hydrophobicity and ion-ion 
interactions as for the other types of chromatography but also hydrogen bond formation.  
The difference is in biospecificity.  There is usually more than one binding site on both 
ligand and target molecule but they are arranged in unique orientation so they fit as lock 
and key.  Similar but less specific molecules can have structure that fits closely and they 
will form a weaker bond with the immobilized ligand.  [65, 66] 
Due to biospecificity, the process of protein separation and purification has to be 
optimized for each ligand and the target molecule but there are some general rules 
applicable to all affinity chromatography procedures.  For example, there is a limited 
36 
 
number of buffer systems that can be used in order to preserve the binding properties of 
the immobilized ligand.  Also, detergents, pH and salt concentration are crucial for 
successful binding event. 
The outcome of affinity chromatography depends on several factors like ligand 
selectivity, ligand stability, recovery, etc.  Ligand stability determines durability and 
versatility of the method.  If, for example, the ligand is stable in different buffer systems 
and under the wide pH range, the method will allow for more options on sample 
preparation side.  Recovery is determined by the amount of the target molecule efficiently 
eluted from the immobilized ligand.  However, ligand selectivity is perhaps the most 
important factor that determines efficient separation and purification.  The immobilized 
ligand is also a protein with its specific amino acid sequence folded in the specific 3D 
structure.  The actual site of affinity binding is the binding pocket of that protein.  Only 
the molecules that can at least loosely fit into the binding pocket will be retained and 
separated from the matrix. 
 
 
Cell disruption and Protein Solubilization 
 
In a biological system, proteins are found within the cell, at the cell membrane as 
well as in the extracellular space.  To that end, cell disruption is a first step in analysis of 
the whole proteome inevitable to access all proteins.  Cells can be disrupted chemically, 
utilizing buffers with various combinations of detergents, or mechanically, utilizing 
ultrasonication, homogenization or mechanical shearing. 
Buffers, as radioimmunoprecipitation assay (RIPA) and nonidet P40, have been 
used for the lysis of Toxoplasma gondii and subsequent lectin pull-down.  [66]  However, 
those detergents pose the risk of decreased lectin viability or even denaturation.  [67] 
Alternative option is mechanical shearing of cells passing them through a narrow 
valve under high pressure in the buffer with no detergents added.  This process disrupts 
the membrane of the cells but detergents are still required to release membrane- or 
cytoskeleton- bound proteins.   
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A natural surroundings of a native protein even in the whole cell lysate is a very 
complex matrix material composed of other proteins, lipids, carbohydrates, salts and 
other biological macromolecules.  Also, proteins are often parts of protein complexes or 
integrated into organelles or plasma membranes and generally insoluble in their native 
state.  Therefore, they have to be denatured to solubilize which means the disruption of 
all disulfide, hydrogen, dipole-dipole and van der Waals bonds as well as electrostatic 
and hydrophobic interactions.  This is achieved by addition of salts, charged detergents, 
chaotropes, and reduction and alkylation reagents to lysis buffers.  However, they are 
very different in their ability to disrupt cells and solubilize proteins and often are used 
together.  Criteria to consider when choosing the lysis buffer: pH, ionic strength, 
detergents and denaturants, proteolysis preventers and protein stability enhancers.  [68] 
Ionic detergents, like SDS, contain a head group with either positive or negative 
charge and are useful for breaking protein-protein interactions.  Micelle size is 
determined by combining the repulsion of the ionic head group with the hydrophobic 
attraction of the side chain.  The size can increase if the charge on the head group is 
neutralized.  Therefore, increasing ionic strength of the solution reduces critical micelle 
concentration (CMC), but temperature change has no effect. 
Non-ionic detergents, like triton X-100, have uncharged hydrophilic group and 
are used for breaking lipid-protein or lipid-lipid interactions.  They gently solubilize 
proteins, retaining their native structure and function.  Unlike ionic detergent, critical 
micelle concentration of non-ionic detergent increases with increased temperature but 
ionic strength of the solution has no effect. 
Zwitterionic detergents, like CHAPS, combine properties of both ionic and non-
ionic detergents.  They are best used for breaking protein-protein interactions.  [69, 70] 
For all of these reasons, when the downstream processing can tolerate the 
presence of detergents, the best approach is to utilize the strengths of both mechanical 
and chemical cell disruption.   
 
 
Protein Purification Techniques  
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 After elution from the Con A column, proteins are obtained in an elution buffer 
whose composition may not be compatible with the next step of the sample preparation.  
For that reason, two most widely used techniques for protein purification, gel 
electrophoresis and dialysis, are discussed below. 
 
 
Gel Electrophoresis 
 
Ever since its introduction in late 1950’ the polyacrylamide gel electrophoresis 
technique (PAGE) is the most widely used method and the golden standard for separation 
and analysis of protein mixtures as well as buffer exchange.  The premise of this 
separation technique is that proteins with different molecular weights and the same 
charge will assume different electrophoretic motilities.  However, proteins are vastly 
diverse with respect to charge as well as 3D structure.  To accomplish separation based 
solely on molecular weight differences, they have to be denatured and saturated with the 
charge which is achieved utilizing sodium dodecyl sulfate (SDS). 
 As an anionic detergent, SDS binds with its hydrophobic tail to hydrophobic 
portions of a protein in a proportion of one SDS anion for every two amino acids.  The 
specific mass ratio is 1.4:1.  This yields an equal charge density per unit length and 
disrupts the three dimensional structure of the protein.  The polar head of this detergent 
interacts with the hydrophilic solution and allows the protein to exist stably in solution in 
its extended conformation.  The outcome of this interaction are denatured and highly 
negatively charged proteins whose migration is not determined by intrinsic charge but by 
molecular weight.  [71] [69] 
In the electric field, applied across the polyacrylamide gel, negatively charged 
SDS-protein complexes move from cathode to anode.  Since they are introduced to the 
polyacrylamide gel from the cathode side they are forced to move through pores of the 
gel.  The rate at which they travel through the gel depends on the strength of the field, 
size and shape of the SDS-protein complex.  However, these are not the only 
determinants in this technique.  Solvent, with its temperature and ionic strength, as well 
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as pH and the counterions with their shielding effect can greatly impact the separation.  
[71, 72] 
 Polyacrylamide gel is obtained by polymerization of the acrylamide monomer 
into long chains and crosslinked with N,N’-methylene-bis-acrylamide (bis) into three-
dimensional structures.   Polymerization starts with the addition of ammonium persulfate 
(APS) and the base N,N,N’,N’-tetramethylenediamine (TEMED) that catalyzes the 
decomposition of persulfate ion to produce a free radical.  This free radical then reacts 
with the acrylamide monomer transferring the charge to each subsequent monomer upon 
binding thus creating a linear polymer.  The occasional bis-acrylamide crosslinks the 
linear polymers creating the sieve-like network whose pore sizes depend on 
concentrations of monomer and the crosslinker.  [71, 72] 
The final gel used for protein separation is a composite of two polyacrylamide 
gels, stacking and resolving that differ in the pore size and pH.   Sample is loaded onto 
the stacking gel that has larger pore size and pH of 6.8.  The purpose of this portion of the 
gel is to focus all proteins into an infinitely thin band before they enter the resolving gel.  
This process utilizes negatively charged chloride and glycine ions from the buffer whose 
pH is 8.3.   
Chloride ions create the cloud around the proteins preventing proteins to see the 
field.  As the chloride ions move through the gel fast, the proteins further from the 
entrance to the resolving gel lose chloride ions earlier than the proteins closer to the 
resolving gel and start to move toward the anode 
Glycine is a weak acid and, therefore, exists as a zwitterion at low pH glycinate 
anion at high pH.  Once the electric field is established, glycine moves from the buffer 
(pH 8.3) to the stacking gel (pH 6.8) towards the anode.  The decrease of pH in the 
stacking gel causes the loss of a portion of the charge on glycine that, consequently, 
moves slower.  The zone between chloride and glycine ions creates a high strength field 
that contains all proteins.  This very thin band moves in this arrangement toward the 
resolving gel.  Once the glycine reaches the resolving gel the increase of pH causes it to 
move faster and it outruns the proteins allowing them to see the electric field. 
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As the result of this process all proteins are focused at the interface of stacking 
and resolving portion of the gel providing separation within the resolving gel based only 
on their mass differences. 
Once the negatively charged proteins reach the resolving gel they are driven by 
the electric field.  However, smaller proteins move faster while the larger proteins have 
more difficulty moving through the pores of the gel.  That is the basic principle of protein 
separation on the polyacrylamide gel.  [71] 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) can be utilized for 
separation as well as purification and concentration.  For separation purposes the gel is 
usually cast between two 7 x 8 cm glass plates separated by 0.5 to 1.5 mm spacer.  
Looking from the top of the gel the stacking portion is about 3 cm long followed by about 
5 cm of the resolving gel where the separation takes place.  However, the benefits of the 
protein stacking process can be used as a buffer exchanger to purify the sample of buffer 
components incompatible with the downstream analysis and to concentrate the proteins 
into finite band.  This technique is called three-layer sandwich gel electrophoresis and 
requires different layout of the gel.   
 
 
Three-Layer Sandwich Gel Electrophoresis 
 
The buffers required for sample preparation and extraction from the cell culture 
are incompatible with the downstream mass spectrometry analysis.  Also, sample loss and 
dilution becomes a significant factor when multiple preparation steps are involved.   
Three-layer sandwich gel electrophoresis (TSGE) is developed with the purpose to 
concentrate the proteins and to serve as a buffer exchanger thus increasing the efficiency 
of the proteomic analysis. 
TSGE protocol combines the properties of agarose and polyacrylamide gels.  As 
the name says, the gel is comprised of three parts.  On the bottom of the cylindrical 
cartridge is 40 % polyacrylamide gel (~ 0.5 cm) that serves as a sealing layer.  It is 
covered with the 12 % polyacrylamide gel (~ 2 mm) where the proteins are concentrated.  
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The top layer is made of 2% agarose gel (~ 3 cm) that is used to immobilize the proteins 
from the sample. 
The combination of pH throughout the gel plays a significant role in concentrating 
the proteins.  The pH ranges from 8.3 in the running buffer through around 7 in agarose 
gel and 6.8 in the concentration layer to 11 in the sealing layer.   
When the current is applied these pH changes influence glycine present in running 
buffer as well as all three layers of the gel.  When glycinate ions enter the agarose gel 
from the running buffer, they lose a portion of charge and move slower.  On the other 
hand, chloride anions move rapidly toward the anode.  This creates the zone of high field 
that contains the proteins and move toward the anode reaching the concentration portion 
of the gel as a narrow band.  At the interface of concentration and sealing layer the pH 
changes from 6.8 to 11 that results in increase of negative charge on glycinate ions that 
now move rapidly toward anode leaving the proteins out of high strength field.  Facing 
the very small pores of a sealing layer, proteins are stopped and accumulate at the 
interface of the concentration and sealing layer.   
After overnight electrophoresis, the whole structure can be pushed out of the 
cartridge to access the concentration layer and prepare it for in-gel digestion.  [73] 
In comparison with other purification techniques TSGE proved to significantly 
improve the protein recoveries and the downstream analysis.  [73]  However, this method 
was tested on buffers containing high concentrations of salts and detergents but not on the 
buffers that contain high concentrations of sugar as elution buffers utilized in lectin 
affinity chromatography. 
 
 
Dialysis 
 
Dialysis is one of the most widely used methods for sample purification and 
buffer exchange by removal of low molecular weight contaminants or solution 
components.   
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The separation is driven by concentration gradient.  It is spontaneous separation 
process in solution, based on the diffusion through a semipermeable membrane with the 
definite pore size allowing only the molecules smaller than the pores to pass through.   
In practice, the two solutions are placed in two different compartments separated 
only by a semipermeable membrane.  The membrane has a definite pore size and only 
molecules below a certain molecular weight can pass through, defining the molecular 
weight cutoff limit (MWCO).  The molecules below MWCO can freely pass through the 
membrane in both directions while larger molecules are retained.  The solution 
containing the analyte of interest and undesired small molecules is in several orders of 
magnitude smaller volume than the target buffer solution.  The purpose of such a 
difference in volume is to maintain the concentration gradient.  Due to the concentration 
gradient across the membrane molecules diffuse from regions of high concentration to 
regions of low concentration.   
Also, the target buffer is stirred in order to increase the diffusion rate.  After 
entering the low concentration buffer the small molecules form a Nernst diffusion layer 
where their concentration is higher in comparison with the bulk volume of the target 
buffer.  This slows down the dialysis due to low local concentration gradient.  However, 
stirring efficiently overcomes this obstacle and maintains high concentration gradient.  
[74] 
The diffusion phenomenon is governed by the Fick’s law:  
 J =  −D ∂ϕ
∂x  
 
J – diffusion flux [mol
m2∙s
],  
D – diffusion coefficient or diffusivity [m
2
s
],  
ϕ – concentration [mol
m3
], and  
x – position [m]. 
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Diffusion flux (J) is the measure of the amount of substance passing through the 
unit area per unit time and depends on the diffusion coefficient and the concentration 
gradient.   
 
Diffusion coefficient (D) is given by Stokes–Einstein equation: 
 D =  kBT6πηr 
 
kB – Boltzman’s constant 1.38 x 10-23 [
J
K
], 
T – absolute temperature [K], 
η – viscosity, and 
r – radius of spherical particle. 
 
D is directly proportional to the temperature but inversely proportional to 
viscosity of the fluid and the size of the particles.  For biological molecules 10-11 < D < 
10-10 m2/s. 
As the concentration gradient (∂ϕ/  ∂x) decreases over time, the system reaches 
equilibrium and concentrations of small molecules in both compartments become equal.  
However, this is avoided by frequent change of the target buffer replenishing the system 
with the new target buffer that is free of the undesired molecules. 
Therefore, the best diffusion is achieved in solutions with high concentration 
gradient, for small molecules in low density solutions at higher temperatures.  [74] 
Dialysis is a simple, low cost technique that depends on several factors as the time 
required for buffer exchange, membrane chemistry and its morphological properties as 
well as the shape of the protein molecules that should not be exchanged between the two 
compartments.  [75] 
Time required to complete the buffer exchange depends on the membrane area 
and temperature.  Larger areas will allow for faster exchange but will also increase the 
loss of protein due to adsorption on the membrane.  The increase in temperature will lead 
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to the faster transport through the membrane due to increased motion of molecules but 
can also degrade the sample.  [75] 
Also, considering that buffer molecules can go through the membrane in both 
directions dialysis can increase the sample volume thus diluting it.  For that reason, the 
samples with low protein concentrations but high salt and detergent concentrations can 
experience significant sample dilution.  This can partially be avoided by stepwise 
dialysis, where the initial target buffer contains a certain amount of the salt and detergent 
to decrease the concentration gradient and prevent the sample dilution.  [75] 
Even though the mechanism of the dialysis remains the same, the technique is 
significantly improved.  The enhanced membrane morphology provides reduced protein 
adsorption and consequential loss.  Also, the commercially available systems allow for a 
wide range of sample volume and convenience for sample handling.  [75] 
 
Glycosylation of the proteins has been recognized as one of the major 
posttranslational modifications responsible for regulation of protein function.  But better 
understanding of processes involving glycoproteins is hampered due to low abundance of 
glycoproteins in the biological systems.  The techniques described in the introductory 
portion of this chapter are tested in attempt to find the best approach for isolation and 
high yield of glycoproteins.   
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Experimental 
 
 
Materials 
 
Neurotensin and vasopressin peptide standards were purchased from Sigma-
Aldrich (St. Louis, MO).   
Tris base, SDS, acrylamide, N,N-methylene-bis-acrylamide (Bis), Laemmli 
sample buffer, ammonium persulfate (APS), N,N,N,N-tetramethylethylenediamine 
(TEMED), glycine, agarose and Coomassie Brilliant Blue G-250 were obtained from 
BioRad (Hercules, CA).   
Trypsin-EDTA (phenol red, 0.05 %) was obtained from Life Technologies (Grand 
Island, NY). Protease inhibitor cOmplete was purchased from Roche Diagnostics 
(Indianapolis, IN).   
Slide-A-Lyzer MINI Dialysis Device, 3.5K MWCO, 2mL and bicinchoninic acid 
assay (BCA) were purchased from Thermo Scientific (Rockford, IL).  Agarose bound 
Concanavalin A (Con A) resin, mannose-BSA, glucose-BSA and glycoprotein eluting 
solution for mannose- and glucose-binding lectins were purchased from Vector 
Laboratories (Burlingame, CA). 
Ammonium bicarbonate, ammonium citrate, formic acid, methanol, Optima grade 
acetonitrile, Optima grade water, calcium chloride dehydrate and manganese chloride 
tetrahydrate were purchased from Fisher Scientific (Chicago, IL).  Sequencing grade 
modified trypsin was supplied by Promega (Madison, WI).   
 
 
Equipment 
 
Electro-Eluter model 422 (BioRad) coupled with a power PAC 1000 power 
supply (BioRad) was used for three-layer sandwich gel electrophoresis.  A Finnigan LCQ 
Deca ion trap mass spectrometer (San Jose, CA) coupled with LC Packings Ultimate 47 
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quaternary capillary LC system (San Francisco, CA) was used for mass spectrometric 
analysis. 
 
 
Instrument Optimization – Effect of Inlet Capillary Temperature 
 
The purpose of the following procedure is to determine the most optimal inlet 
capillary temperature.  Vasopressin and neurotensin were dissolved in mobile phase made 
of 94.9% water, 5% of acetonitrile and 0.1% of formic acid and used as standard 
peptides.  Single charged ions of vasopressin and neurotensin are 1085.4 and 1030. 5 
respectively, while their double charged ions are 542.7 and 515.7 respectively. 
The instrument was set up for the syringe infusion and tuned.  The ratio of single to 
double charged ions at different temperatures was measured for both peptides using that 
tuning file while constantly infusing the standard peptide solution and acquiring data.  
Intensity of each ion was averaged over 10 minute time frame.  The temperature was 
changed in increments.  The temperature at which the double charged ions are favored is 
chosen for semi-automatic retuning.  The new tuning file and the inlet capillary 
temperature were used for mass spectrometry analysis. 
The effect of the inlet capillary temperature was also examined when a 
chromatographic separation was included.  For that reason neurotensin was analyzed at 2 
temperatures (150 °C and 220 °C) using the tuning files for each temperature, 
chromatographic separation utilizing gradient elution (load method of MudPit) and C18 
column. Gradient elution was 110 minutes long.  
The mobile phase composition was first held at the appropriate mix of solvents C and 
D for 15 min (0 to 15 min), and then was switched to solvent A for additional 2 min (15 
to 17 min).  The gradient was linearly changed from 100% to 50% over 48 min (17 to 65 
min) and from 50% to 20% over 20 min (65 to 85 min).  The mobile phase composition 
was returned to 100% of solvent A in 5 min (85 to 90 min) and held at 100% for the next 
20 min (90 to 110 min).   
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Cell Culture Growth, Maintenance and Lysis 
 
HeLa cell lines were maintained in α-Minimal Essential Medium (α-MEM) 
supplemented with 7% dialysed fetal bovine serum, 2 mM L-glutamine, 100 U/mL 
penicillin, and 100 μg/mL streptomycin. 
Since the tissue culture media contains Ca2+ and Mg2+ ions and proteins from fetal 
calf serum (FBS) that can inhibit trypsin, the plates containing confluent layer of HeLa 
cells were washed with sterile PBS then covered with 0.05 % trypsin solution and 
incubated for 4 minutes at 37 °C to release them from substratum.   
 Cells were transferred to 14 mL test tube and centrifuged for 5 minutes at 2000 
rpm.  The media was removed and the cell pellet was washed with PBS and centrifuged 
again.  The washing procedure was performed 3 times in total.   
The cell lysis was performed in two different buffers.  One of the samples was 
dissolved in 1 mL of RIPA buffer (10 mM tris-HCl (pH 7.5), 140 mM NaCl, 0.5% (w/v) 
sodium deoxycholate, 0.1% (w/v) SDS, 0.025% (w/v) sodium azide, 2 % (v/v) TritonX-
100).  Cells were lysed by passage through a 27 ½ gauge needle.  Whole cell lysates were 
centrifuged (2000 rpm, 5 min) to remove unlysed cells and cell debris.  Supernatants of 
multiple lysates were merged together and taken for further analysis.    
The other cell lysis sample was dissolved in 1 mL of 10 mM tris buffer (pH 7.5) 
with 150 mM NaCl.  Cells were lysed by passage through a 27 ½ gauge needle.  Whole 
cell lysates were centrifuged as described above.  Supernatants of multiple lysates were 
merged together and taken for further analysis.   
Protein concentration was determined by bicinchoninic acid assay (BCA) 
according to manufacturer’s instructions. 
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Lectin Pull-down 
 
 
Cell Lysate Preparation 
 
To the HeLa cell lysate calcium chloride and manganese chloride were added to 
the final concentration of 1 mM.  Also, protease inhibitor as well as SDS to the final 
concentration of 0.05 % were added to the volume containing 1 mg of protein, 
determined by BCA. 
 
 
Con A Column Preparation 
 
Three Con A columns were freshly prepared for each sample.  Two milliliters of 
settled Con A resin were placed in each 5 mL plastic filter tube with the frit at the 
bottom.  Each resin was washed with 15 mL of the column wash buffer (10 mM Tris, pH 
7.5, 150 mM NaCl, 1 mM CaCl2 and 1mM MnCl2).  Immediately after preparation the 
sample was applied to the column. 
 
 
The Pull-down Procedure 
 
Depending on the protein concentration, 3-4 mL of the whole cell lysate were 
applied to the first Con A column and incubated over night at 4 °C on the rotator (Figure 
3.6).  The following day the flow through fraction from the first column was applied 
directly to the freshly prepared second Con A column.  To ensure all the flow through 
exited the first column, 1.5 mL of column wash buffer was applied to the first column 
and the flow through was caught in the second column until the flow stopped.  The 
second column is then placed on the rotator and incubated over night at 4 °C.   
The first column was washed with 15 mL of column wash buffer.  Four milliliters 
of commercially obtained Vector Labs elution solution were applied to the first column 
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and incubated for 4 hours at room temperature on the rotator.  Glycoproteins were eluted 
from the column directly into two dialysis cups.  To ensure all the Vector Labs elution 
solution exited the first column, 1.5 mL of 25 mM ammonium bicarbonate buffer was 
applied to the column and eluate was caught until the flow stopped. The eluate, divided in 
two dialysis cups, was dialyzed for 24 hours against 9 L of 25 mM ammonium 
bicarbonate buffer. 
 
Figure 3.6. The pull-down procedure. 
 
The following day, the procedure was repeated for the second and third column.  The 
flow through fraction from the second column was applied directly to the freshly 
prepared third Con A column.  To ensure all the flow through exited the second column, 
1.5 mL of column wash buffer was applied to the second column and the flow through 
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was caught in the third column until the flow stopped.  The third column is then placed 
on the rotator and incubated over night at 4 °C.   
The second column was washed with 15 mL of the column wash buffer.  Four 
milliliters of Vector Labs elution solution were applied to the second column and 
incubated for 4 hours at room temperature on the rotator.  Glycoproteins were eluted 
from the column directly into two dialysis cups.  To ensure all the Vector Labs elution 
solution exited the second column, 1.5 mL of 25 mM ammonium bicarbonate buffer was 
applied to the column and eluate was caught until the flow stopped. The eluate, divided in 
two dialysis cups, was dialyzed for 24 hours against 9 L of 25 mM ammonium 
bicarbonate buffer. 
The final day of the sample preparation, glycoproteins from the third Con A 
column were eluted.  The flow through fraction was stored at -20 °C and the column was 
washed with 15 mL of the column wash buffer.  Four milliliters of Vector Labs elution 
solution were applied to the third column and incubated for 4 hours at room temperature 
on the rotator.  Glycoproteins were eluted from the column directly into two dialysis 
cups.  To ensure all the Vector Labs elution solution exited the third column, 1.5 mL of 
25 mM ammonium bicarbonate buffer was applied to the column and eluate was caught 
until the flow stopped. The eluate, divided in two dialysis cups, was dialyzed for 24 hours 
against 9 L of 25 mM ammonium bicarbonate buffer. 
The columns for all samples were made of fresh Con A resin to avoid sample 
contamination. 
 
 
Dialysis 
 
 Proteins were eluted from the Con A column with 4 mL of Vector Labs elution 
solution.  Since the capacity of the dialysis cup was only 2 mL, the eluate was placed into 
2 dialysis cups with molecular weight cutoff limit of 3.5 kDa.  The cups were placed on 
the holder and the bottom was submerged in 1.5 L of stirred 25 mM ammonium 
bicarbonate pH 8, as shown in the (Figure 3.7).  Ammonium bicarbonate solution was 
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replaced every 2 hours for four times and after 4 hours the fifth time.  The sixth and final 
1.5 L of ammonium bicarbonate was left over night.   
The following day the membrane on the bottom of the dialysis cups was sealed 
with parafilm to prevent leakage and sweating of the regenerated cellulose membrane and 
the cups were placed in their 50 mL test tube.  The samples were now ready for digestion. 
 
 
Figure 3.7.  A. Dialysis set-up. B. Closer look at the regenerated cellulose membrane. 
 
 
The Three-layer Sandwich Gel Electrophoresis 
 
A three-layer sandwich gel was prepared in 5 mL plastic filtration tube with the 
frit at the bottom.  The gel was consisted of an acrylamide sealing layer at the bottom, an 
acrylamide concentration layer in the middle and an agarose loading layer on the top.   
The tube was sealed with the stopper during the preparation process to prevent 
liquid leakage before the polymerization completion. 
The gel and the sample were made according to the recipes and procedures 
outlined in the publication by Liu et. al.  [73] 
Briefly, the monomer solution for the sealing layer was loaded to the tube, 
covered by 200 μL of a 1-butanol and allowed to polymerize for 30 minutes after which 
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the monomer solution for the concentration layer was loaded to the tube, covered by 200 
μL of a 1-butanol and also allowed to polymerize for 30 minutes.   
The solution of 10 % SDS was added to the sample and incubated at 60°C for 10 
minutes.   Agarose loading layer, containing the sample, was prepared according to the 
recipe, quickly transferred to the tube and allowed to cool at 4°C for 10 min.  At the end, 
10 μL of 0.5% agarose with 1% Bromphenol Blue was overlaid on the gel to monitor 
electrophoresis.  Running buffer was prepared according to the Laemmli’s protocol.  [76]  
The gel was run at 15V for 30min, 5V overnight and at gradually increased voltage to 
150V until the dye front was at the interface of the concentration and the sealing layer. 
 
 
Sample Preparation for Mass Spectrometric Analysis 
 
Digestion of proteins for the dialyzed samples was performed by adding a trypsin 
solution directly to the dialysis cup and incubating for 18 hours at 37 °C water bath.  The 
amount of added trypsin varied depending on the elution.  To the eluate from the first 
column 10 µg of trypsin was added, while 5 µg each were added to the second and third 
eluate.  After digestion, the peptides were transferred to 1.5 ml test tube and dried using 
vacuum centrifuge.   
Digestion of proteins obtained by TSGE method started with excising the 
concentration layer of the gel and cutting it to the smallest pieces.  These pieces were 
placed in the 1.5 mL test tube and covered with 50 mM ammonium bicarbonate buffer. 
After 10 minutes incubation at room temperature the buffer was removed and the pieces 
were covered with the buffer consisted of equal amounts of acetonitrile and 50 mM 
ammonium bicarbonate.  After 10 minutes incubation at room temperature that buffer 
was replaced with the pure acetonitrile and incubated for additional 10 minutes at room 
temperature yielding dried gel pieces.  After removal of acetonitrile the pieces were 
covered with the solution of trypsin in 25 mM ammonium bicarbonate and incubated at 4 
°C for 40 minutes.  During that time the gel pieces swelled by absorbing the trypsin 
solution.  The excess solution was removed and enough of 25 mM of ammonium 
bicarbonate was added to cover the gel pieces.  After this, the gel pieces, closed in the 1.5 
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mL test tube were incubated at 37 °C overnight.  The following day peptides were 
recovered by transferring the buffer solution into the new 1.5 mL test tube. Remaining 
gel pieces were further extracted with 100%acetonitrile and transferred to the buffer tube.  
The resulting peptide solution was dried using vacuum centrifuge.   
Dried peptides obtained from any of the two procedures described above were 
reconstituted in 20 µL of a mobile phase containing 94.9 % optima water, 5 % of optima 
acetonitrile and 0.1 % formic acid and analyzed by Finnigan LCQ Deca ion trap mass 
spectrometer utilizing MuDPIT method. 
 
 
Mass Spectrometry Analysis 
 
Finnigan LCQ Deca ion trap mass spectrometer coupled with a LC Packings 
Ultimate quaternary capillary LC system was used for the mass spectrometry analysis of 
peptides. 
Twenty microliters of digested glycoproteins obtained from the whole HeLa cell 
lysate were injected onto a laboratory fabricated fused silica capillary strong cation 
exchange (Partisil SCX) column (350 μm I.D. x 5 cm, 10 μm particles).  This column 
was directly connected to a laboratory fabricated fused silica capillary C18 column (350 
μm I.D. x 15 cm, Microsphere 3.5 μm particles).  Columns were packed using a stainless 
steel packing cell.  LC Packings Ultimate quaternary capillary LC system with a 20 µL 
injection loop was used for the sample and mobile phase delivery at 4 µL/min.    
Mobile phase A was comprised of 94.9% optima grade water, 5% optima grade 
acetonitrile and 0.1% formic acid.  Mobile phase B was comprised of 94.9% optima 
grade acetonitrile, 5% optima grade water and 0.1% formic acid.   Mobile phase C was 
comprised of 300 mM ammonium acetate in optima grade water and mobile phase D was 
the same composition as mobile phase A.   
Two-dimensional LC separation was performed with 12 isocratic salt elution 
where the following salt concentrations of 0 mM, 5 mM, 10 mM, 15 mM, 20 mM, 30 
mM, 40 mM, 50 mM, 100 mM, 150 mM 225 mM and 300 mM were obtained by 
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appropriately mixing mobile phase C with mobile phase D.  The 13th salt step was 
obtained by direct injection of 20 µL of 3 M ammonium acetate.   
Each salt elution was followed by a 110 min C18 reversed-phase gradient elution.  
The mobile phase composition was first held at the appropriate mix of solvents C and D 
for 15 min (0 to 15 min), then was switched to solvent A for additional 2 min (15 to 17 
min).  The gradient was linearly changed from 100% to 50% over 48 min (17 to 65 min) 
and from 50% to 20% over 20 min (65 to 85 min).  Mobile phase composition was 
returned to 100% of solvent A in 5 min (85 to 90 min) and held at 100% for the next 20 
min (90 to 110 min).   
The voltage applied to electrospray source was 3.5 kV and 20 units of sheath gas 
flow.  I Inlet capillary was held at 35.0 V and 150 °C.  Other parameters were as follows: 
tube lens offset at -15.0 V, multipole 1 offset at -7.5 V, lens voltage at -50.0 V, multipole 
2 offset at -13.0 V, multipole RF amplitude peak-peak at 400 V, entrance lens at -50.0 V 
and trap DC offset at -10.0 V.   
Mass spectrometer was operated in a data-dependent mode.  The full scan from 
m/z 200 to 2000 was acquired first.  The most intense precursor ion was selected from the 
previous full MS scan and submitted to collisional induced dissociation (CID) with an 
activation Q of 0.250, activation time of 45 ms, and 35% normalized collision energy 
(NCE).  This was followed by a MS/MS scan between m/z 200 and 2000 of the most 
intense ion of the previous full MS scan.  The same procedure was performed for three 
most intense ions that were excluded from further tandem experiments for one minutes.   
Each analytical full scan was constructed as an average of 3 full scans, while each 
analytical MS/MS scan was constructed as an average of 5 MS/MS scans.   
Maximum ion trap injection time of 300 ms was used for the full scans and 500 
ms was used for MS/MS scans.   Automatic gain control (AGC) target for the full scan 
was set to 2 x 107 and for MS/MS to 5 x 107. 
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Protein Data Analysis 
 
All 13 RAW files of a MuDPIT run were uploaded to the MASCOT daemon 
software, combined as one file and searched against SwissProt, human taxonomy.   
Parameters were set as followed: cleavage enzyme was trypsin with three missed 
cleavage allowed.  Peptide tolerance and the MS/MS tolerance were set to 1.0 Da.  
Oxidized methionine was chosen as a variable modification.   
MudPIT scoring was used and the requirement for positive protein identification 
was bold red.  This requires the protein hit to include at least one bold red peptide match 
indicating that the peptide is the highest scoring match to the MS/MS spectra. 
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Results and Discussion 
 
 
Instrument Optimization – Effect of Inlet Capillary Temperature 
 
C-terminus of peptides digested with trypsin have arginines (R) or lysines (K), 
two most basic or hydrophilic amino acids.  Their carboxylic groups are neutral (COOH) 
in the solution due to free formic acid in the mobile phase.  The first proton will reside at 
the residue of R or K making NH3+ of initial NH2 because that is the most nucleophilic 
group.  This proton will not change its place in the process of excitation and 
fragmentation.  This would lead to loss of information about the sequence.  However, the 
second proton can be anywhere along the backbone and reside at any carbonyl group. 
Upon excitation, the peptide can fragment anywhere along the peptide bond yielding two 
charged fragments permitting detection of both.  In a population of a certain peptide there 
will be a statistical distribution of proton locations that will give different fragments 
allowing us to determine the peptide sequence.  For all these reasons it is imperative to 
have at least 2+ precursor ions for the MS/MS analysis. 
Increased temperature of the inlet capillary increases the statistical probability of 
singly charged precursor ions because the high kinetic energy increases the breakage of 
hydrogen bonded water that can take the proton along with it.  Therefore, it is necessary 
to determine the optimal inlet capillary temperature. 
Two commercially available peptides, neurotensin and vasopressin, were separately 
infused into mass spectrometer.  Data were acquired continuously but intensity of ions 
was averaged over 10 minute time frame when the temperature of the capillary was 
equilibrated.  The temperature was changed incrementally and plotted against the average 
ratio of intensity of single-to-double charged ions for a given temperature (Figure 3.8).  
The higher abundance of double charged ions was confirmed for the temperature of 150 
°C. 
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Figure 3.8.  Inlet capillary temperature optimization with infusion for neurotensin and 
vasopressin. 
 
The ratio of single and double charged ions was also examined with chromatographic 
separation utilizing neurotensin as standard peptide.   Results show higher abundance of 
double charged ions at 150 °C (Figure 3.9) and that temperature was chosen as optimal 
for further work.   
 
 
Figure 3.9.  Inlet capillary temperature optimization with chromatographic separation for 
neurotensin. 
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Cell Disruption method and Protein Denaturation 
 
The choice of the cell lysis and protein denaturation method depends on 
compatibility with downstream analysis.  For the analysis of glycoproteins, cell lysate is 
applied to the Con A column, therefore, the buffer containing the cell lysate has to be 
chosen so that Con A retains its binding activity.  Con A is found to tolerate up to 0.05% 
of SDS, 1% of Triton-X and NP-40.  On the other hand, RIPA buffer is one of the most 
efficient buffers used for the cell lysis.  Hence, the stability of the Con A column was 
tested for the cell lysate in RIPA buffer.  
Figure 3.10.  Elution profile of mannose-BSA (1 mg/mL) in RIPA buffer. 
 
Results, shown in the Figure 3.10, represent the protein concentration in 250 µL 
fractions calculated by measuring the absorbance at 280 nm.  Fractions were caught from 
the gravity flow Con A column.  Mannose-BSA was used as a standard protein to bind to 
the Con A and was eluted with the Vector Labs elution solution. 
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The highest protein concentrations were detected in the flow through fractions 
confirming that Con A lost its binding activity thus eliminating RIPA buffer as a choice 
for the cell lysis. 
Mechanical shearing is alternative approach that disrupts the membrane of the 
cells but detergents are still required to release membrane- or cytoskeleton- bound 
proteins.  Also, proteins retain their native structure preventing efficient digestion 
downstream. 
Following the elution, digestion is the next step in sample preparation that needs 
to be considered when choosing cell lysis and denaturation method.  Trypsin is the most 
widely used protease that specifically cleaves proteins at carboxyl terminus of arginine or 
lysine unless there is adjacent proline.  Peptide fragments with one missed cleavage are 
common due to blocked or slowed digestion, for example in the case of multiple adjacent 
cleavage sites or if an acidic residue is on either side of the cleavage site.  Also when the 
protein is in its natural folded state not all arginines and lysines are accessible for 
digestion.  Therefore, detergents are used to unfold and denature the proteins allowing for 
more efficient digestion.  On the other hand, trypsin is also a protein, and therefore, 
sensitive to the presence of detergents.  Trypsin retains most of its activity in 0.1% (w/v) 
SDS solution.   
All things considered, heating the cell lysate containing low amount of SDS at 95 
°C for 5 minutes was reported as viable alternative.  [77]  The increase in temperature 
increases the kinetic energy of the protein, which disrupts the weak bonds and allows for 
equally probable multiple microstates of the protein to exist.  Consequently, entropy 
raises and protein’s random structure is favored, which facilitates digestions due to more 
accessible cleavage sites. 
To explore this approach, the new batch of HeLa cells was lysed in tris buffer and 
0.05% SDS was added post lysis obtaining aliquots for 2 samples.   Samples were treated 
exactly the same except one of them was heated 95 °C for 5 minutes and cooled to the 
room temperature before applying on to Con A column.  The cooling to the room 
temperature was necessary because the sample was applied to the Con A, which is also a 
protein and, therefore, prone to denaturation at high temperatures. 
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Figure 3.11.  The effect of cell lysate heating to the qualitative identification of the 
proteins.  Purple circle: no heat involved. Red circle: heated sample. 
 
Results, shown in the Figure 3.11, suggest that heating the sample does not 
increase the number of identified proteins.  As the increase in temperature results in 
protein unfolding, cooling process allows for random refolding of denatured proteins 
decreasing the number of accessible cleavage sites. This results in long peptides with 
multiple missed cleavages that fall outside of the analytical window of the mass 
spectrometry method and thus lower the number of identified proteins.  However, due to 
randomness some cleavage sites remain accessible allowing for additional 66 proteins 
from the heated sample to be identified.  The heating approach was abandoned since it 
yielded overall less proteins.  
In conclusion, the cells were lysed in 10 mM tris buffer, pH 7.5, 0.15 M NaCl and 
protease inhibitor.  To prevent foam formation 0.05% SDS was added after lysis as well 
as 1 mM CaCl2 and 1 mM MnCl2 required for subsequent binding to Con A. 
 
 
Elution Buffer Evaluation 
 
Con A binds glycoproteins containing α-mannose, α-glucose and N-glycans on 
their surface when the whole cell lysate at the neutral pH containing calcium and 
manganese is applied to ConA column.  Applying binding inhibitors, such as methyl-α-
D-mannopyranoside, will release glycoproteins from binding pocket of Con A.  The 
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release is further enhanced by removal of metal ions and decrease of the pH when Con A 
reversibly loses its binding ability.  However, low pH is not suitable for downstream 
protein digestion due to reversible inactivation of trypsin.  Therefore, the solution of 
binding inhibitor at neutral pH is preferred because it eliminates the need for subsequent 
buffer exchange.  
Achieving a complete elution with the in-house prepared binding inhibitor 
solution can be difficult while commercially available solutions promise a complete 
elution but are a proprietary blend of unknown composition thus requiring a subsequent 
buffer exchange.  For that reason we tested two elution solutions.  The first was in-house 
made tris buffer without added metal ions at pH 7.5 containing 0.2 M methyl-α-D-
mannopyranoside.  The second elution solution (Vector Labs elution solution, ES 1100) 
with pH 3.0 and undisclosed composition was purchased.   
Two samples, of the same protein concentration and otherwise treated the same, 
were eluted from the Con A column using either tris buffer at pH 7.5 or commercially 
obtained solution at pH 3.0. 
 
 
Figure 3.12.  The effect of the composition of elution solution on the qualitative 
identification of proteins.  Green circle: Vector Labs elution solution.  Blue circle: 10 
mM tris pH 7.5 with 0.2 M α-methyl-mannoside and 0.2 M α-methyl-glucoside. 
 
 Results, shown in the Figure 3.12, prove more efficient elution utilizing 
commercially obtained solution. However, not all proteins identified utilizing tris buffer 
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are also identified using the Vector Labs elution solution probably due to pH sensitivity 
of those proteins. Nevertheless, the Vector Labs elution solution was chosen for further 
sample processing.   
 
 
Development of glycoprotein purification method 
 
The purification method set up is outlined in the Figure 14.  In brief, the whole 
cell lysate was applied to the first Con A column.   Non-retained protein fraction (first 
flow-through) was passed through a second Con A column and then the second non-
retained protein fraction (second flow-through) was passed through the third Con A 
column yielding 3 sequential pull-downs.   
Glycoprotein eluting solution was applied to each column to elute the retained 
protein fraction.  Glycoproteins were eluted from the column directly into two dialysis 
cups and dialysed against 25 mM ammonium bicarbonate buffer. 
After dialysis the bottom of the dialysis cup was sealed and proteins were 
digested directly in the cup by adding a trypsin solution.  After digestion, peptides were 
dried using vacuum centrifuge and reconstituted in a mobile phase appropriate for the 
mass spectrometry analysis utilizing MuDPIT method.   
To achieve the best yield of this method development the steps of this protocol 
were individually assessed and optimized.  For that purpose HeLa whole cell lysate was 
utilized as benchmark.    
 
 
Comparison of three layer sandwich gel and dialysis for purification of glycoproteins 
 
Glycoproteins are eluted in commercially obtained, very viscous Vector Labs 
elution solution incompatible with the downstream tryptic digestion due to low pH of 3.0.  
Adjusting the pH of the blank Vector Labs elution solution (no proteins) with ammonium 
hydroxide invoked precipitation.  For that reason, the solution containing eluted proteins 
had to be exchanged with 25 mM ammonium bicarbonate pH 8 that is preferred solution 
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for the tryptic digestion.  Thus two methods were evaluated: three layer sandwich gel and 
dialysis.   
 
 
Three layer sandwich gel electrophoresis 
 
As described in introductory part of this chapter, three layer sandwich gel 
electrophoresis (TSGE) proved to be superior clean-up method for the protein solutions at 
near neutral pH, containing high concentrations of salts and detergents.  [73]  However, 
protein solution obtained after elution from the Con A column contains high saccharide 
concentration at pH 3.0 in proprietary solution due to elution with the Vector Labs 
elution solution.  Therefore, TSGE has to be evaluated for this settings as well.   
To that end, BSA coupled with glucose (g-BSA) was commercially obtained and 
used as a standard.  The standard sample was prepared by dissolving 400 µg (10 µL 
stock) of g-BSA in 390 µL of Vector Labs elution solution.  This standard sample was 
loaded and TSGE was run.  In spite of running the gel for 28 hours the bromophenol 
blue, considered as zero molecular weight marker, never reached the concentration layer 
but was observed in the middle of the agarose gel.  Nevertheless, the concentration layer 
was excised and treated as if proteins were prepared for the mass spectrometry analysis.  
However, the mass spectrometry analysis showed no significant protein hits raising the 
question if the problem was Vector Labs elution solution or the protein glycosylation.   
These two questions were obvious because the Vector Labs elution solution 
already showed precipitation when attempting to adjust the pH from 3.0 to 7.5.  On the 
other hand, saccharides are hydrophilic but uncharged compounds. Therefore, 
glycosylated proteins extensively decorated with saccharides may not be able to see the 
electric field due to the shielding effect of saccharides on the protein surface.  To give an 
answer to this question two experiments were performed.   
The first experiment involved comparison of TSGE of glycosylated protein 
standards versus non-glycosylated protein standards, both diluted with Vector Labs 
elution solution to the same concentration yielding 2 samples.  Both samples, g-BSA and 
non-glycosylated BSA, of the same concentrations were prepared from their respective 
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standard stock solutions by dilution in Vector Labs elution solution and TSGE was run.  
Both samples yielded same results with the bromophenol blue in the middle of agarose 
gel and no significant protein hits by mass spectrometry.   
To exclude protein glycosylation as a possible impediment for TSGE 
methodology, the next set of two samples were prepared exactly the same as described in 
the paragraph above except the protein stock solutions were dissolved in solution 
containing 10 mM tris buffer, pH 7.5, 0.15 M NaCl and 0.2 M α-methyl-mannoside as a 
binding inhibitor. In both samples the bromophenol blue was found at the bottom of the 
concentration layer after the overnight run.  The concentration layer was excised and 
samples were prepared for mass spectrometry analysis.  BSA was identified in both 
samples confirming that protein glycosylation does not pose an obstacle for TSGE 
methodology. 
The next experiment addressed the question of the compatibility of Vector Labs 
elution solution with TSGE and for that reason no proteins were included in this 
experiment.  To that end four samples with the decreasing concentrations of the 
commercially obtained eluting buffer (100%, 75%, 50%, 25% and 0% in tris buffer) were 
prepared according to the recipe for TSGE sample preparation.  Additionally, two 
samples containing decreasing concentrations of binding inhibitor (α-methyl-mannoside) 
were also prepared in tris buffer, pH 7.5, with 0.15 M NaCl to examine effects of the 
monosaccharide on the TSGE gel.   Gels were run over night as outlined in the protocol 
for TSGE.  [73]   Results are shown in the Figure 21. 
Bromophenol blue dye has a molecular weight of 670 g/mol and is negatively 
charged at neutral pH thus migrating at the same direction as proteins in the electric field.  
For that reason, besides using the color of bromophenol blue to visualize the progress of 
the experiment, this dye can be used as a “zero molecular weight” marker, which was 
exactly its purpose in this experiment.   
It is obvious from the Figure 2.13 that the movement of bromophenol blue depends 
on the concentration of Vector Labs elution solution but not on the concentration of the 
binding inhibitor; the higher the concentration of the Vector Labs elution solution the less 
movement of the dye.  Dye moved 22.2% further down the agarose gel when the 
concentration was decreased by 25%.  However, this is not a linear dependence because 
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the dye moved 77.8% further down the agarose gel when the concentration was decreased 
by 50% of its initial concentration.  It is evident that diluting the Vector Labs elution 
solution to 25% of its initial concentration leads to bromophenol blue reaching the 
concentration layer.  But that would not be feasible when eluting the glycoproteins with 4 
mL of Vector Labs elution solution because the dilution would yield 16 mL of much 
diluted sample known to suffer of high protein loss in subsequent sample treatment.   
Considering gels containing the binding inhibitor in tris buffer, the concentration of 
the binding inhibitor has no effect on the bromophenol blue movement in the electric 
field.  Therefore, some other component of proprietary Vector Labs elution solution is 
causing the problem. 
As previously stated, the pH adjustment of the Vector Labs elution solution led to 
precipitation.  Out of curiosity if the precipitate formed within the gel as well, gels were 
stored at 4 °C for 2 days to allow the dye to diffuse and then visualize the site of the dye 
build-up (Figure 3.14).  
  
 
Figure 3.13.  Sandwich gel with dye in different concentrations of ES-1100 or Tris + α-
methyl- mannoside elution solution. 
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Figure 3.14.  Sandwich gel with dye in different concentrations of ES-1100 or Tris + α-
methyl-mannoside elution solution after 2 days in 4°C. 
 
Even after the dye diffused throughout the gel the white precipitate was obvious 
in two gels with the highest concentration of Vector Labs elution solution but less so in 
the third and fourth gel where the concentrations were 50% and 25% respectively (Figure 
3.14).   
These experiments led to conclusion that TSGE method is not suitable for use 
with Vector Labs elution solution (ES-1100) due to precipitation within the agarose gel.  
For that reason another method had to be considered and dialysis was the next logical 
option. 
 
 
Dialysis 
 
Dialysis is one of the most widely used methods for sample purification and 
buffer exchange by concentration gradient driven separation based on the diffusion 
through a semipermeable membrane.  However, one of the draw-backs of dialysis is loss 
of proteins because they tend to stick to the membrane as well as the wall of the plastic 
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cup.  For that reason digestion was conducted within the cup allowing for parts of the 
stuck proteins to be digested.  Even though digestion of those proteins would not be 
complete, available peptides would contribute to their identification consequently 
increasing the number of the identified proteins.   
In practice, 3 mg of whole cell lysate was applied to the Con A column and 
incubated overnight at 4 °C.   Retained proteins were eluted with 4 mL of Vector Labs 
elution solution into two dialysis cups and dialyzed against 25 mM ammonium 
bicarbonate for 24 hours.  The following day trypsin was added directly to the dialysis 
cups and proteins were digested overnight.  After the sample was dried and reconstituted 
in the mobile phase, mass spectrometry analysis was performed utilizing MuDPIT 
separation.   
As a result 295 proteins were identified with false discovery rate of 17.03% and 
highest score of 964 making this procedure a method of choice for buffer exchange. 
 
 
Sequential Pull-down Method 
 
 Binding of glycoproteins to a lectin depends on how well does the exposed glycan 
fit into the binding pocket of the lectin.   Glycan that fits better will replace the weakly 
bound ones due to increase of the bond strength and decrease of the free energy of the 
bound state.   Therefore, weakly bound proteins can be replaced by proteins that bind 
more tightly.   
To analyze glycoproteins with the lower binding affinity sequential pull-down 
method was evaluated.  In this method the sample was applied to the first Con A column 
and the non-retained protein fraction (first flow-through) was passed through a second 
Con A column and then the second non-retained protein fraction (second flow-through)  
was passed through the third Con A column (3 sequential pull-downs).  Employing the 
sequential pull-down glycoproteins that bind with the highest affinity are retained in the 
first pull-down allowing for the weaker bound ones to be retained in the next pull-down 
and even weaker in the third one. 
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To that end, 3 mg of the whole cell lysate were applied to the Con A column and 
processed as described.  Results, shown in the Figure 3.15, prove that flow through after 
the first and second pull-down still contain glycosylated proteins.  Even though vendor 
claims 1 mL of settled Con A resin can capture 4 mg of ovalbumin, these results prove 
that 1.5 mL of settled Con A resin cannot capture all glycoproteins in 3 mg of the whole 
cell lysate.  After the second pull-down, 39 additional proteins were identified and 32 
after the third pull-down.  In total, 366 proteins were detected, which is 19.4% more than 
with only the first pull-down.  
As mentioned before, the whole cell lysate contains 0.05% SDS.  Even though 
Con A is not denatured by such low concentration of SDS, there is still a possibility that a 
certain percentage of Con A molecules will lose their activity.  Besides the binding 
strength explained above, this activity loss can be another reason for identifying unique 
proteins in the second and third pull-down.  Moreover, proteins can bind in non-specific 
fashion in any of the three columns thus increasing the number of unique proteins 
identified in any of the three pull-downs.  
 
 
Figure 3.15.  Sequential pull-down.  Purple circle: first pull-down.  Orange circle: second 
pull-down.  Yellow circle: third pull-down. 
 
Reproducibility of this approach was evaluated with the analysis of three samples 
of the same amount of protein (1.4 mg).  Samples were all prepared from the same whole 
cell lysate and treated the same.  Results of the total number of identified proteins in each 
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samples are presented in the table 3.2 below along with the highest protein score and 
false discovery rate (FDR). 
 
Table 3.2.  Results of the triplicate sample analysis. 
sample # protein FDR highest score 
1 159 16.35% 955 
2 193 12.16% 1091 
3 226 11.51% 1815 
 
On average 193 proteins were identified with the standard deviation of 34.   
However, utilization of mass spectrometry and bioinformatics tools provide 
deeper understanding of the obtained results, therefore, further validation of this method 
of isolation of glycoproteins can increase the confidence in database searching results.  A 
better understanding of results starts with understanding of types of acquired peptides and 
their fragmentation products.  Some peptides have N-glycosylation consensus sequence 
as a part of the amino acid sequence but some do not.  Peptides with the consensus 
sequence may carry a glycan attached to it but not all of them do.  The most abundant 
peptides that reach ion trap undergo fragmentation.  The peptide fragmentation can be 
invoked anywhere along the peptide backbone breaking the peptide bonds.  The fragment 
that carries the charge is the detected ion that can be identified by the search against the 
protein database for the particular organism.  However, glycans attached to peptides can 
produce ions of larger mass or even sterically block trypsin to access the cleavage sites 
due to their elaborate structure and prevent the digestion of that site.  [78]  For those 
reasons many peptides will not be identified because their masses do not match the 
masses of the peptides in the database.  If the glycan is very complex and introduces a 
much larger increase in mass or the peptide has multiple missed cleavages, the mass of 
that peptide may not fall within the detection range of the mass spectrometer used 
preventing the ion to even be detected.  However, if the mass of the glycan is known and 
not too large, the mass of the expected ion can be calculated and the perceived peptide 
can be searched manually.  But that does not mean that peptides with the consensus 
sequence cannot be identified automatically.  About two thirds of proteins that contain 
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the consensus sequence are actually glycosylated.   Remainders are identified as potential 
N-glycan sites.  Therefore, it is possible to identify peptides with the consensus sequence 
but experimental proof of N-glycan is required.  For all these reasons, some peptides with 
the consensus sequence will be detected but some will not.  One example of such 
occurrence is endoplasmin that is used here as an example of the identified proteins and 
thereof analysis.  
Endoplasmin precursor has a nominal mass of 92411, 803 amino acids sequence 
and calculated pI value of 4.76.  In UniProtKB/Swiss-Prot database it is listed under the 
code P14625 (ENPL_HUMAN) and under the name “endoplasmin”.  This molecular 
chaperone is found in endoplasmatic reticulum and helps transport and process secreted 
proteins.  It also serves in ER-associated degradation (ERAD) of terminally misfolded or 
unassembled proteins.  [79]  
Utilizing this method, endoplasmin was identified with the score of 368 with 
sequence coverage of 43%.  The protein sequence is shown below with the identified 
peptides in red color and the ones that were not identified in black color. 
 
 
Considering consensus sequence for N-glycosylation there are 8 possible N-
glycosylations sites (underlined) but only two, at Asn-217 and Asn-445, have been 
reported (underlined and bold italic).  [80]   
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Even more details can be obtained on the peptide level. For example, let’s 
consider the ion 638.75 m/z from the list of ions assigned to endoplasmin (Figure 3.16).  
Since 638.75 m/z ion is doubly charged, it was identified with the mass of 1275.48 m/z 
for the singly charged ion.  Singly charged ion was matched with the neutral peptide with 
calculated monoisotopic mass of 1274.64 m/z.  The fragmentation pattern of 638.75 m/z 
ion was matched with the sequence ELISNASDALDK. Out of 129 predicted ions shown 
in the table 3.3, 29 were identified (bold) by analysis of 36 most intense peaks shown in 
the mass spectrum below. 
 
 
 
Figure 3.16. Mass spectrum: A. Full mass spectrum (MS),  B. Mass spectrum of 
fragmented ion (MS/MS) 
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Table 3.3.  List of expected fragment ions of the ion 638.75 m/z. Detected in bold. 
 
 Considering chromatograms (Figure 3.17), if only total ion chromatogram at 
38.15 minutes no discernable peaks are observed.  However, if the chromatogram of only 
a single ion is extracted the peak is obvious. 
 
 
Figure 3.17.  Chromatogram: A. Total ion chromatogram, B. Single ion chromatogram 
for the ion 638.75 m/z. 
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In light of the fast development of bioinformatics tools, one could argue that 
identified glycoproteins could be extracted from the list of identified proteins from the 
whole cell lysate acquiring only proteins with appropriate consensus sequence and hence 
significantly decrease the sample handling time.  However, there are two obstacles to that 
simplified approach.  First, a protein can have multiple consensus sequences but glycans 
will not be attached to all of them.  Hence the glycosylation has to be confirmed and the 
lectin binding is a viable conformation.  The second obstacle is the sample complexity.  
Glycosylation of the human proteome is at the level of 5%.  Since only the most abundant 
proteins are identified, glycoproteins would compete for identification with a large 
number of other proteins in the mixture and thus would very likely not to be identified.  
Therefore, the reduction in sample complexity utilizing the lectin pull-down method 
provides a substantial advance in protein identification. 
 
 
Conclusion  
 
Up to date, there is no one method capable of profiling all proteins present in the 
whole cell lysate. Therefore, sample separation and purification methods are developed 
as an answer to the particular question about the proteome.  Sample preparation for mass 
spectrometry analysis is a critical step in the proteomics workflow because the quality 
and reproducibility of sample extraction and preparation significantly impacts the 
separation and identification capabilities of mass spectrometers.  The additional obstacle 
is to extract only glycosylated proteins for which there is no one standard method.   
The method discussed in this chapter was developed in an effort to identify as 
many as possible N-glycosylated proteins.  This is achieved by application of the whole 
cell lysate to agarose bound Concanavalin A (Con A) beads to efficiently pull down 
glycoproteins, dialyze and analyze them using MuDPIT.  This method was further 
enhanced by passing the non-retained protein fraction (first flow-through) through a 
second Con A column and then passing the second non-retained protein fraction (second 
flow-through) through the third Con A column (3 sequential pull-downs) yielding 366 N-
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glycosylated proteins.  Utilizing three sequential pull-downs rather than just one, the 
number of identified proteins was increased by 19.4%. 
Considering the tendency of proteins to stick to the plastic surfaces, this method 
was crafted with minimal protein loss in mind.  That was achieved by minimizing the 
number of steps in the procedure as well as the equipment.  Although the use of more 
elaborate separation protocols could increase the depth of protein coverage, there will 
always be peptides that are out of the analytical window and will not be identified. 
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CHAPTER 4 
GLYCOPROTEOMES OF TACHYZOITES AND TISSUE CYSTS 
AND THEIR DIFFERENCIES 
 
 
Toxoplasma gondii 
 
Toxoplasma gondii, as a member of Apicomplexa phylum, is obligate intracellular 
protozoan parasite that causes the disease called toxoplasmosis.  Even though humans are 
accidental hosts, some estimates suggest that over 30 % of human population is infected.   
Infected humans could have parasite colonies anywhere in brain or muscle tissue.  
Therefore, human symptoms of toxoplasmosis may depend on parasite’s final location 
explaining, for example, the newly found link between schizophrenia and toxoplasmosis.  
[81] 
Recent studies show that a Toxoplasma gondii found in the brain of mammals 
encodes the enzyme for producing dopamine and as consequence production and release 
of significantly higher than normal amount of dopamine in infected brain cells.  These 
findings may change the way dopamine-related neurological disorders as schizophrenia, 
attention deficit hyperactivity disorder and Parkinson's disease are treated.  [81] 
Most infected people are healthy and do not exhibit any symptoms or develop 
sore lymph nodes, muscle pains and other minor flu-like symptoms that last for only 
several weeks.  However, for those who are immune-suppressed, and particularly for 
fetus, there are significant health risks that can occasionally be fatal.  [81] 
Life cycle of Toxoplasma gondii starts with the sexual cycle in its feline definitive 
hosts.  The cat sheds parasites in the form of oocysts that take 1 to 5 days to sporulate and 
become infective.  Asexual cycle starts once the intermediate hosts such as birds, rodents, 
humans, etc. ingest the material contaminated with oocysts that shortly after transform 
into rapidly growing tachyzoites.  Once tachyzoites are localized in brain or muscle tissue 
they develop into tissue cysts containing bradyzoites.  [82] 
Bradyzoites and tachyzoites are two interconvertable stages of Toxoplasma gondii 
in intermediate hosts.  Transmissible bradyzoites are growing slowly making a dormant, 
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encysted form.  Upon ingestion the cysts’ wall is digested releasing bradyzoites.  Being 
resistant to gastric proteases, they invade the small intestine where they convert into 
rapidly growing, infectious tachyzoites.  This form replicates inside a parasitophorous 
vacuole (PV), egress, and then infects neighboring cells.  Host’s immune system 
eliminates most of parasites but enough of them survive and convert back into 
bradyzoites and wait until a member of a feline family ingests the intermediate host to 
finish their life cycle.  [82]  
Toxoplasmosis can be treated with combinations of antibiotics as pyrimethamine, 
which interfere with RNA and DNA synthesis, with either trisulfapyrimidines or 
sulfadiazine that stops folic acid production in parasite but Toxoplasma gondii cannot be 
eliminated completely.   Parasites can remain within tissue cells in a less active stage 
(cyst) in locations difficult for medication to get to. 
All this calls for better understanding of Toxoplasma gondii that will point toward 
possible cure.  The whole proteome of Toxoplasma gondii is yet to be annotated and this 
dissertation represents the effort put toward developing a method to study the 
glycoproteome of intracellular organisms and consequently increase the knowledge base 
of Toxoplasma gondii. 
 
 
Structure of Toxoplasma gondii 
 
Toxoplasma gondii is a part of Apicomplexa phylum named after distinct apical 
complex structure involved in penetrating a host's cell. 
Toxoplasma gondii goes through three infectious stages: tachyzoites (rapidly 
multiplying), bradyzoites (slow growing) and sporozoites.  [83]  This dissertation focuses 
on tachyzoites and tissue cysts containing bradyzoites. 
Tachyzoites and bradyzoites have a similar structure. They are both crescent 
shaped, 2 to 6 µm long with pointed front end and rounded back end.  They consist of 
triple membrane system called pellicle and subpellicular microtubules, apical rings, polar 
rings, conoid, rhoptries, micronemes, micropore, endoplasmic reticulum, Golgi complex, 
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ribosomes, rough and smooth endoplasmic reticulum, micropore, mitochondrion, 
nucleus, dense granules, amylopectin granules and apicoplast.  [83] 
However, there are some differences as the appearance, position and number of 
some organelles.  The structure of rhoptries of tachyzoites look like labyrinth while 
bradyzoites have uniformly dense rhoptries with some of them folded back on 
themselves.  Also the nucleus in bradyzoites is positioned toward the front end while 
more centrally located in tachyzoites.   Higher numbers of micronemes and dense 
granules are reported in tachyzoites, while the higher number of amylopectin granules is 
observed in bradyzoites.  Also, bradyzoites are less prone to proteolytic digestion than are 
tachyzoites.  [83]  
While tachyzoites grow in groups called clones, bradyzoites grow within tissue 
cysts.  The wall of the tissue cyst is about 0.5 µm thick and elastic and composed of the 
host cell and parasite materials.  Tissue cysts vary in size depending on the cyst age, from 
5 µm for young cysts containing as few as two bradyzoites to 70 µm for the older cysts 
that can contain several hundred bradyzoites.  [83] . 
 
 
Glycoproteome of Toxoplasma gondii 
 
Unlike Toxoplasma gondii, majority of members of Apicomplexa phylum cannot 
form the tissue cysts.  Those members are proved to lack enzymes required for the 
Asparagine Linked Glycan (ALG) pathway.  However, the analysis of the genome of 
Toxoplasma gondii proves the ability of the parasite for N-linked glycosylation 
suggesting that N-linked glycosylation may play a key role in the establishment and 
maintenance of the tissue cyst.  [84] 
Glycosylation of tachyzoites of Toxoplasma gondii proteins has been a 
controversial issue and demonstrated only recently using lectin pull-down methods and 
mass spectrometry that showed the great diversity of glycoproteins in Toxoplasma gondii.  
[66, 77, 85, 86]  However, the mechanism of transformation of tachyzoites to bradyzoites 
and the tissue cyst formation is yet unknown.  Also, little is known about the 
glycoproteome of tissue cysts except their affinity to react with Dolichos biflorus 
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agglutinin (DBA) (Figure 4.1) and succinyl Wheat Germ Agglutinin (SWGA) lectins.  
[66]  Combining DBA and Con A staining (Figure 4.2) demonstrates the presence of α-
linked mannose on the bradyzoites but not the cyst wall.   
The evidence suggests that glycosylation could be essential for cyst formation and 
maintenance which is characteristic of chronic stage of disease.  Therefore, further 
studies are required to better understand the interaction between Toxoplasma gondii and 
its host in order to develop new preventative and therapeutic strategies.   
 
Figure 4.1.  Staining of the tissue cyst. DAPI: Hoechst staining binds to DNA and each 
blue spot is an individual parasite.  DBA: Dolichos biflorus agglutinin lectin binds to α-
linked N-acetylgalactosamines, which are abundantly present on the cyst wall.  DIC: dif 
 
 
Figure 4.2.  Staining of the tissue cyst. DBA, stained in green, highlights the cyst wall. 
Concanavalin A (Con A), stained in red, recognizes α-linked mannose. 
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Experimental 
 
 
Materials 
 
Trypsin-EDTA (phenol red, 0.05 %) was obtained from Life Technologies (Grand 
Island, NY). Protease inhibitor cOmplete was purchased from Roche Diagnostics 
(Indianapolis, IN).   
Slide-A-Lyzer MINI Dialysis Device, 3.5K MWCO, 2mL and bicinchoninic acid 
assay (BCA) were purchased from Thermo Scientific (Rockford, IL).  Agarose bound 
Concanavalin A (Con A) resin and glycoprotein eluting solution for mannose- and 
glucose-binding lectins were purchased from Vector Laboratories (Burlingame, CA). 
Ammonium bicarbonate, ammonium citrate, formic acid, methanol, Optima grade 
acetonitrile, Optima grade water, calcium chloride dehydrate and manganese chloride 
tetrahydrate were purchased from Fisher Scientific (Chicago, IL).  Sequencing grade 
modified trypsin was supplied by Promega (Madison, WI).   
 
 
Equipment 
 
A Finnigan LCQ Deca ion trap mass spectrometer (San Jose, CA) coupled with LC 
Packings Ultimate 47 quaternary capillary LC system (San Francisco, CA) was used for 
mass spectrometric analysis.  Thermo French Pressure Cell Press (Rockford, IL) was 
utilized for cell lysis. 
 
 
Cell Culture Growth and Maintenance 
 
Tachyzoites ME49 were grown in the Vero cell line. Vero cells were maintained 
in α-Minimal Essential Medium (α-MEM) supplemented with 7% heat-inactivated fetal 
bovine serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin.  
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Plates with confluent Vero monolayers were infected with 1 x 106 parasites and incubated 
at 37 °C until the majority of the Vero cells lysed out.  The content of the plates was 
transferred to the 14 mL test tube and centrifuged at 2000 rpm for 10 minutes.  Parasites 
and parasites containing cells were resuspended in 1 mL PBS and selectively lysed by 
passage through a 27 gauge needle.  After centrifugation the obtained parasite pellet was 
washed three times by sequential centrifugation and resuspension in 10 mL sterile PBS.  
The final pellet was obtained after centrifugation at 2000 rpm for 10 minutes.  Pellets 
from multiple plates were merged together and resuspended in 10 mM tris (pH 7.5) with 
150 mM NaCl and protease inhibitor.  French press at a pressure of 10,000 psi at medium 
setting was utilized for parasite lysis.   
The purified brain cysts were obtained from Dr Sinai’s laboratory.  They were 
harvested from CBA/J mice around 3-4 weeks post infection and purified by percoll 
gradient purification.  Purified cysts were prepared for the mass spectrometry analysis 
following the same protocol as used for tachyzoites.  
 
 
Lectin Pull-down 
 
Cell Lysate Preparation 
 
Parasite pellets, tachyzoites or bradyzoites, were resuspended in 10 mM tris 
buffer (pH 7.5) with 150 mM NaCl and lysed utilizing French press at a pressure of 
10,000 psi at medium setting.  Protein concentration was determined by bicinchoninic 
acid assay (BCA) according to manufacturer’s instructions.  Calcium chloride and 
manganese chloride to the final concentration of 1 mM, protease inhibitor as well as SDS 
to the final concentration of 0.05 % were added to the cell lysate containing 1 mg of 
protein, determined by BCA.   
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Con A Column Preparation 
 
Three Con A columns were prepared for each sample.  Two milliliters of settled 
Con A resin were placed in each plastic filter tube.  Each resin was washed with 15 mL 
of buffer containing 10 mM Tris (pH 7.5), 150 mM NaCl, 1 mM CaCl2 and 1mM MnCl2.   
 
 
The Pull-down Procedure 
 
Depending on the protein concentration, 3-4 mL of the parasite lysate were 
applied to the first Con A column and incubated over night at 4 °C on the rotator.  The 
following day the flow through fraction from the first column was applied directly to the 
freshly prepared second Con A column.  To ensure all the flow through exited the first 
column, 1.5 mL of column wash buffer was applied to the first column and the flow 
through was caught in the second column until the flow stopped.  The second column is 
then placed on the rotator and incubated over night at 4 °C.   
The first column was washed with 15 mL of column wash buffer.  Four milliliters 
of glycoprotein eluting solution were applied to the first column and incubated for 4 
hours at room temperature on the rotator.  Glycoproteins were eluted from the column 
directly into two dialysis cups.  To ensure all the Vector Labs elution solution exited the 
first column, 1.5 mL of 25 mM ammonium bicarbonate buffer was applied to the column 
and eluate was caught until the flow stopped. The eluate, divided in two dialysis cups, 
was dialyzed for 24 hours against 9L of 25 mM ammonium bicarbonate buffer. 
The following day the procedure was repeated for the second and third column.  
The flow through fraction from the second column was applied directly to the freshly 
prepared third Con A column.  To ensure all the flow through exited the second column, 
1.5 mL of column wash buffer was applied to the second column and the flow through 
was caught in the third column until the flow stopped.  The third column is then placed 
on the rotator and incubated over night at 4 °C.   
The second column was washed with 15 mL of the column wash buffer.  Four 
milliliters of glycoprotein eluting solution were applied to the second column and 
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incubated for 4 hours at room temperature on the rotator.  Glycoproteins were eluted 
from the column directly into two dialysis cups.  To ensure all the Vector Labs elution 
solution exited the second column, 1.5 mL of 25 mM ammonium bicarbonate buffer was 
applied to the column and eluate was caught until the flow stopped. The eluate, divided in 
two dialysis cups, was dialyzed for 24 hours against 9 L of 25 mM ammonium 
bicarbonate buffer. 
The final day of the sample preparation glycoproteins from the third Con A 
column were eluted.  The flow through fraction was stored at -20 °C and the column was 
washed with 15 mL of the column wash buffer.  Four milliliters of glycoprotein eluting 
solution were applied to the third column and incubated for 4 hours at room temperature 
on the rotator.  Glycoproteins were eluted from the column directly into two dialysis 
cups.  To ensure all the Vector Labs elution solution exited the third column, 1.5 mL of 
25 mM ammonium bicarbonate buffer was applied to the column and eluate was caught 
until the flow stopped. The eluate, divided in two dialysis cups, was dialyzed for 24 hours 
against 9 L of 25 mM ammonium bicarbonate buffer. 
Columns for all samples were made of fresh Con A resin to avoid sample 
contamination. 
 
 
Dialysis 
 
Proteins were eluted from the Con A column with 4 mL of Vector Labs elution 
solution.  Since the capacity of the dialysis cup was only 2 mL, the eluate was placed into 
2 dialysis cups with molecular weight cutoff limit of 3.5 kDa.   Cups were placed on the 
holder and the bottom was submerged in 1.5 L of stirred 25 mM ammonium bicarbonate 
pH 8.  Ammonium bicarbonate solution was replaced every 2 hours for four times. The 
fifth solution was replaced after 4 hours.  The sixth and final 1.5 L of ammonium 
bicarbonate were left over night.   
The following day, membranes on the bottom of dialysis cups was sealed with 
parafilm to prevent leakage and sweating of the regenerated cellulose membrane and cups 
were placed in their 50 mL test tube.  Samples were now ready for digestion. 
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Sample Preparation for Mass Spectrometric Analysis 
 
Digestion of proteins was performed by adding trypsin solution directly to the 
dialysis cup and incubating for 18 hours at 37 °C water bath.  The amount of added 
trypsin varied depending on the elution.  To the eluate from the first column 10 µg of 
trypsin was added, while 5 µg each were added to the second and third eluate. 
After digestion, peptides were transferred to 1.5 ml Eppendorf tube and dried 
using vacuum centrifuge.   Peptides were reconstituted in 20 µL of a mobile phase 
containing 94.9 % optima water, 5 % of optima acetonitrile and 0.1 % formic acid and 
analyzed by Finnigan LCQ Deca ion trap mass spectrometer utilizing MuDPIT method. 
 
 
Mass Spectrometry Analysis 
 
Finnigan LCQ Deca ion trap mass spectrometer coupled with a LC Packings 
Ultimate quaternary capillary LC system was used for the mass spectrometry analysis of 
peptides. 
Twenty microliters of digested glycoproteins obtained from the parasite lysate 
were injected onto a laboratory fabricated fused silica capillary strong cation exchange 
(Partisil SCX) column (350 μm I.D.  x 5 cm, 10 μm particles).  This column was directly 
connected to laboratory fabricated fused silica capillary C18 column (350 μm I.D.  x 15 
cm, Microsphere 3.5 μm particles).  Columns were packed using a stainless steel packing 
cell.  LC Packings Ultimate quaternary capillary LC system with a 20 µL injection loop 
was used for the sample and mobile phase delivery at 4 µL/min.    
Mobile phase A was comprised of 94.9% optima grade water, 5% optima grade 
acetonitrile and 0.1% formic acid.  Mobile phase B was comprised of 94.9% optima 
grade acetonitrile, 5% optima grade water and 0.1% formic acid.   Mobile phase C was 
comprised of 300 mM ammonium acetate in optima grade water and mobile phase D was 
the same composition as mobile phase A.   
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Two-dimensional LC separation was performed with 12 isocratic salt elution 
where following salt concentrations of 0 mM, 5 mM, 10 mM, 15 mM, 20 mM, 30 mM, 
40 mM, 50 mM, 100 mM, 150 mM 225 mM and 300 mM were obtained by appropriately 
mixing mobile phase C with mobile phase D.  The 13th salt step was obtained by direct 
injection of 20 µL of 3 M ammonium acetate.   
Each salt elution was followed by a 110 min C18 reversed-phase gradient elution.  
Mobile phase composition was first held at the appropriate mix of solvents C and D for 
15 min (0 to 15 min), then was switched to solvent A for additional 2 min (15 to 17 min).   
Gradient was linearly changed from 100% to 50% over 48 min (17 to 65 min) and from 
50% to 20% over 20 min (65 to 85 min).  Mobile phase composition was returned to 
100% of solvent A in 5 min (85 to 90 min) and held at 100% for the next 20 min (90 to 
110 min).   
The voltage applied to electrospray source was 3.5 kV and 20 units of sheath gas 
flow. I Inlet capillary was held at 35.0 V and 150 °C.  Other parameters were as follows: 
tube lens offset at -15.0 V, multipole 1 offset at -7.5 V, lens voltage at -50.0 V, multipole 
2 offset at -13.0 V, multipole RF amplitude peak-peak at 400 V, entrance lens at -50.0 V 
and trap DC offset at -10.0 V.   
The mass spectrometer was operated in a data-dependent mode.  Full scan from 
m/z 200 to 2000 was acquired first.  The most intense precursor ion was selected from the 
previous full MS scan and submitted to collisional induced dissociation (CID) with an 
activation Q of 0.250, activation time of 45 ms, and 35% normalized collision energy 
(NCE).  This was followed by a MS/MS scan between m/z 200 and 2000 of the most 
intense ion of the previous full MS scan.  The same procedure was performed for three 
most intense ions that were excluded from further tandem experiments for one minutes.   
Each analytical full scan was constructed as an average of 3 full scans, while each 
analytical MS/MS scan was constructed as an average of 5 MS/MS scans.   
A maximum ion trap injection time of 300 ms was used for the full scans and 500 
ms was used for MS/MS scans.  The automatic gain control (AGC) target for the full scan 
was set to 2 x 107 and for MS/MS to 5 x 107. 
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Protein Data Analysis 
 
All 13 RAW files of a MuDPIT run were uploaded to the MASCOT daemon 
software, combined as one file and searched against Toxoplasma gondii database 
(http://toxodb.org/toxo/).  Parameters were set as followed: the cleavage enzyme was 
trypsin with three missed cleavage allowed.  Peptide tolerance and the MS/MS tolerance 
were set to 1.0 Da.  Oxidized methionine was chosen as a variable modification.   
MudPIT scoring was used and the requirement for positive protein identification 
was bold red.  This requires the protein hit to include at least one bold red peptide match 
indicating that the peptide is the highest scoring match to the MS/MS spectra. 
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Results and Discussion 
 
 Toxoplasma gondii is intracellular parasite that has several life stages.  Two 
stages that allow asexual expansion of the parasite are stages of tachyzoites and 
bradyzoites.  Tachyzoite is a rapidly growing stage responsible for dissemination during 
acute infection while bradyzoite is a slow growing stage when tissue cysts are formed. 
Utilizing methodology described in Chapter 2, a total of 394 N-glycosylated 
proteins, from tachyzoites ME49 strain, were identified with 57 proteins identified in all 
three replicates and 71 identified in at least two replicates (Figure 4.3).   
 
 
Figure 4.3.  Toxoplasma gondii ME49, tachyziotes, pull-down triplicate.  Purple circle: 
first pull-down replicate.  Orange circle: second pull-down replicate.  Yellow circle: third 
pull-down replicate. 
 
Triplicate analysis shows that majority of proteins is identified in one out of three 
analyses.  However, the closer look of the analyzed proteins reveals that the efficiency of 
the pull-down method depends on molecular weight of the protein (Figure 4.4).  This was 
obtained by dividing all identified proteins in three groups: proteins identified in all three 
replicates, proteins identified in two out of three replicates and proteins identified in at 
least one replicate.  Each group was further divided in three subgroups according to the 
molecular weight of the protein: MW < 30 kDa, 30kDa < MW < 100 kDa and 100 kDa < 
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MW.  The number of proteins in each subgroup was normalized to the total number of 
proteins in each group and expressed as a percentage.  The result of this analysis shows 
that proteins with molecular weight higher than 100 kDa are predominantly observed in 
one out of three replicates while proteins with molecular weight lower than 30 kDa are 
largely observed in all three replicates.    
 
 
Figure 4.4.  Pull-down method dependence on molecular weight of the protein.  X-axis 
indicates in how many replicates were proteins of a certain molecular weight observed 
out of three replicates.  Y-axis indicates the percentage of proteins of a certain molecular 
 
 This observation points out the possibility of pull-down method refinement in the 
future with the purpose to reduce the variability between replicates.  To be more specific, 
after cell lysis proteins could be separated according to their molecular weight utilizing 
size-exclusion chromatography.  However, discussion of results obtained in this 
dissertation is based on proteins identified in all three replicates.  
In general, interpretation of data from a subproteome obtained by the enrichment, 
as in this case glycoproteome, will always suffer from some degree of contamination.  
For example, a glycoprotein could be interacting with the organelle or transported 
through the membrane at the time of extraction, and therefore, not be isolated by the 
enrichment procedure.  Or a non-glycosylated protein could be interacting with the 
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glycoprotein, and therefore, be isolated with the enrichment procedure.  For that reason, 
reproducible sample preparation and replicate analysis is crucial.   
Therefore, the discussion of tachyzoite glycoproteome focuses on 57 proteins 
identified in all three replicates (table 3.1) indicating glycosylation as PTM.  All other 
proteins can be found in the tables A.1 and A.2 in the Appendix.  
 
 
Invasion related glycosylated proteins 
  
Dense granules, rhoptry and micronemes are secretory organelles specialized for 
invasion and modification of the host cell.  The entry of the parasite to the host cell starts 
with the adhesion proteins secreted by micronemes, which assist rhoptry proteins to form 
the moving junction resulting in parasitophorous vacuole.   
Comparing the distribution of 57 identified proteins (table 4), obtained utilizing 
the methodology described in chapter 2, 8 are associated rhoptry (ROP 1, ROP 2A, ROP 
7, ROP 8, ROP 11, ROP 15, ROP 40 and RON 4) and 4 with dense granule organelle 
(GRA 1, GRA 2, GRA 7, GRA 8).  However, proteins associated with micronemes 
proteins were not identified.   
Part of the moving junction macromolecular complex is rhoptry neck protein 
RON 4.  RON 4 is exposed on the cytosolic side of the host cell during invasion and 
binds C-terminal region of β-tubulin of the host early in invasion.  [87]  All rhoptry 
proteins are associated with parasitophorus vacuole, either the ones injected through it 
into the host cell during invasion or responsible for establishment of parasitophorus 
vacuole.   
Dense granule proteins also produce two types of proteins. One type is associated 
with the formation of specialized tubules through which the parasite acquires nutrients 
from the host.  The other type is secreted into the host cell.  [88]   
Recently, a lot of effort has been put in evaluating vaccine antigens.  [89, 90]  
Some of the candidates, such as GRA 1, GRA 7, ROP 1 and ROP 2A were identified in 
this analysis and listed in the table 4.  All dense granule proteins induce a strong T and B 
cell responses of the host, but all infectious stages of Toxoplasma gondii express GRA 7 
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indicating it as a good candidate for the vaccine antigen.  But even stronger immune 
response was obtained when GRA 7 was coupled with ROP 1. [89]  ROP 1 is penetrating 
enhancing factor secreted into the nascent parasitophorous vacuole increasing the 
efficiency of invasion.  Another couple for the vaccine antigen is ROP 2A and SAG 1.  
Glycosylation was found on ROP 2A, the protein that plays a role in association between 
the parasitophorous vacuole and host cell mitochondria.  [91]  
Out of 10 dense granule proteins, where all are associated with parasitophorous 
vacuole, GRA1, GRA2 and GRA8 were also identified utilizing method developed in 
chapter 2 of this dissertation.  GRA 1 and GRA 2 are part of the tubulovesicular 
membranous network, the structure that allows small molecule trafficking.  [92] 
Serine-threonine phosphatase 2C (PP2C), found among glycosylated proteins, 
targets the host nucleus during the invasion facilitated by rhoptry secretion.  However, 
the invasion completion is not required for delivery of this effector protein [93] 
suggesting a possible epigenetic alteration of the host protein expression.  Also, serine-
threonine phosphatase 2C is found as part of the toxofilin–actin–PP2C complex where it 
selectively dephosphorylates toxofilin at serine 53 promoting toxofilin’s affinity to G-
actin.  [94] 
One more enzyme found among glycosylated proteins is protein disulfide 
isomerase.  Protein disulfide isomerase is localized on the surface of Toxoplasma gondii 
where it regulates interactions between parasite and the host cell also making it a good 
candidate for the vaccine antigen.  [95] 
Elongation factor 1-alpha (EF-1-ALPHA) is a putative protein in Toxoplasma 
gondii but it is characterized in other members of phylum where it is also involved in 
invasion pathway.  [96]  
Considering all these findings, it is interesting observation that initial adhesion of 
the parasite to the host cell, regulated by micronemes proteins, does not involve 
glycosylated proteins, while the subsequent steps such as formation of parasitophorous 
vacuole as well as tubule formation proteins and secretory proteins are glycosylated 
indicating those glycoproteins as a viable target for future studies in successful infection 
prevention.  Also, glycosylation is found in proteins not associated with invasion but with 
maintenance of parasite within the host cell.  
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Energy related glycosylated proteins 
 
Several proteins associated with energy pathways were identified as glycosylated.  
One of these is adenosylhomocysteinase.  This is a putative protein with catalytic activity 
and probably involved in energy transfer due to NAD-binding domains. Adenylate 
kinase, another putative protein, is a phosphotransferase.  Dihydrolipoyllysine-residue 
succinyltransferase component of oxoglutarate dehydrogenase is acyltransferase that 
takes part in tricarboxylic acid cycle.  Glyceraldehyde-3-phosphate dehydrogenase 
GAPDH1 is one of the key glycolytic enzymes. Another putative protein is GDP 
mannose 4,6-dehydratase that catalyzes hydrolysis of GDP-mannose to GDP-4-dehydro-
6-deoxy-D-mannose.  These findings indicate involvement of glycosylation in parasites 
metabolic pathways. 
 
 
DNA and translational machinery related glycosylated proteins 
 
A number of DNA and translational machinery related proteins were identified as 
glycosylated.  
One of DNA related proteins is high mobility group (HMG) box domain-
containing protein class II, found in many eukaryotic chromosomal proteins and 
transcription factors, is a non-histone chromosomal protein that binds to the bent or 
distorted DNA.   
SWI2/SNF2-containing PHD finger protein is a zinc-finger that exerts helicase 
activity, DNA binding and ATP binding activity.  PHD finger protein from other 
organisms play a role in chromatin remodeling processes and histone acetylation.  [97] 
Histones are small, highly alkaline proteins responsible for packing DNA in 
nucleosomes.  Epigenetic gene regulation heavily relies on posttranslational 
modifications of histones.  Histones, H2A, H2B, and H4 are predicted for Toxoplasma 
gondii.  The study described in this dissertation reveals glycosylation on H2A1, H2AZ, 
H4, and, surprisingly, H2Bb.  H2B isoforms are expressed depending on the life cycle 
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stage.  H2Ba is expressed in tachyzoites while H2Bb is expressed only during the sexual 
stage of the life cycle but not in tachyzoites nor bradyzoites. H4 is highly conserved 
while H2A and H2B are prone to changes due to their exposed N-terminal tail.  [98] 
Proteins involved in translation seem to have a glycosylated member at every 
stage of the process from initiation (eIF-5A, putative) through elongation (elongation 
factor 2 family protein, putative) to regulation.  Prolyl-tRNA synthetase (ProRS) and 
tryptophanyl-tRNA synthetase (TrpRS2) are aminoacyl-tRNA synthetase located in 
cytoplasm involved in regulation of translational fidelity and tryptophanyl-tRNA 
aminoacylation respectively.  Ribosomal protein RPL24 is a located on the surface of the 
large subunit of a ribosome.  RPL24 is involved in kinetics of peptide synthesis and 
probably in interactions between the large and small subunits.  Ribosomal protein RPS13 
is essential for binding of the small ribosomal subunit to intersubunit of a ribosome.  
 
 
Other identified glycosylated proteins 
 
GTP-binding protein putative regulates G proteins (guanosine nucleotide-binding 
proteins) that are known molecular switches. 
Three chaperones were also identified as glycosylated proteins.  Two of them are 
heat shock homologs HSP 70 and HSP 90 and the third is chaperonin protein BiP.  HSP 
70 is highly expressed by the host cells where inhibits mitochondrial apoptosis of the 
host.  [99]  HSP 90 chaperone machinery is involved in parasite development and can be 
found in a complex with HSP 70.  [100]  Since HSP 70 and HSP 90 can form a complex 
it is unclear if only one of the pair is glycosylated while the other is extracted only due to 
complex formation.  Chaperonin protein BiP is found in endoplasmatic reticulum where 
it is involved in controlling protein folding and exit from the endoplasmatic reticulum.  
[101] 
Perhaps the most important finding in this study is the identification of 
hypothetical proteins.  In total 14 hypothetical proteins were identified not only in all 
three replicates but also majority of them with the high score.   
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Figure 4.5.  Distribution of identified glycoproteins according to function. 
 
To easier comprehend the current body of knowledge of glycosylation the results 
are presented in a pie chart (Figure 4.5) having in mind the function of identified 
glycoproteins.  One third of N-glycosylated proteins are structural proteins mainly 
involved in invasion and establishment of infection pointing to a group of proteins 
already under consideration as a vaccine antigen candidates.  At the same time a 
prominent group of hypothetical proteins reveals that a field of glycoproteomics of 
Toxoplasma gondii is still in its infancy offering a chance for improvement, which was 
the goal of this dissertation.   
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Table 4.1.  Proteins identified in three out of three replicates. 
protein 
# 
protein name ID # mass 
Mowse 
score 
queries 
matched 
1 actin ACT1 (ACT1)  TGME49_209030 41907 532 52 
2 
actin depolymerizing 
factor ADF (ADF) 
 TGME49_220400 12922 46 17 
3 
adenosylhomocysteinase, 
putative 
 TGME49_225050 64105 39 53 
4 adenylate kinase, putative  TGME49_224900 28560 100 25 
5 
alpha tubulin TUBA1 
(TUBA1) 
 TGME49_316400 50113 223 35 
6 
ATPase family associated 
with various cellular 
activities (AAA) domain-
containig protein 
 TGME49_230830 540153 35 195 
7 chaperonin protein BiP  TGME49_311720 73252 286 52 
8 
dense granule protein 
GRA2 (GRA2) 
 TGME49_227620 19804 554 78 
9 
dense granule protein 
GRA7 (GRA7) 
 TGME49_203310 25919 160 29 
10 
dense granule protein 
GRA8 (GRA8) 
 TGME49_254720 28628 34 6 
11 
dihydrolipoyllysine-
residue 
succinyltransferase 
component of 
oxoglutarate 
dehydrogenase 
 TGME49_219550 50125 150 44 
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Table 3.1.  (continued) 
12 
elongation factor 1-alpha 
(EF-1-ALPHA), putative 
 TGME49_286420 49005 1111 128 
13 
GDP mannose 4,6-
dehydratase, putative 
 TGME49_238940 41717 53 19 
14 
glyceraldehyde-3-
phosphate dehydrogenase 
GAPDH1 (GAPDH1) 
 TGME49_289690 53339 60 50 
15 
GTP-binding protein, 
putative 
 TGME49_214350 44547 38 26 
16 
heat shock protein HSP70 
(HSP70) 
 TGME49_273760 72880 438 51 
17 
heat shock protein HSP90 
(HSP90) 
 TGME49_288380 81932 150 44 
18 histone H2A1  TGME49_261250 19546 321 62 
19 histone H2AZ  TGME49_300200 15920 373 98 
20 histone H2Bb  TGME49_251870 12575 197 55 
21 histone H4  TGME49_239260 11439 397 41 
22 
HMG (high mobility 
group) box domain-
containing protein 
 TGME49_210408 10682 91 75 
23 hypothetical protein  TGME49_294430 100125 53 58 
24 hypothetical protein  TGME49_321680 40660 45 30 
25 hypothetical protein  TGME49_297430 25336 70 20 
26 hypothetical protein  TGME49_221470 61517 99 33 
27 hypothetical protein  TGME49_275650 101158 92 50 
28 hypothetical protein  TGME49_279420 144941 69 67 
29 hypothetical protein  TGME49_212860 107698 53 62 
30 hypothetical protein  TGME49_240080 122320 51 74 
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Table 3.1.  (continued) 
31 hypothetical protein  TGME49_268760 31988 36 31 
32 hypothetical protein  TGME49_268260 86736 51 60 
33 hypothetical protein  TGME49_223640 180412 35 89 
34 hypothetical protein  TGME49_310970 370390 40 234 
35 hypothetical protein  TGME49_315570 9273 140 26 
36 hypothetical protein  TGME49_248160 122417 52 71 
37 
inositol polyphosphate 
kinase 
 TGME49_268920 50014 36 33 
38 
NAC domain-containing 
protein 
 TGME49_205558 20507 66 21 
39 
prolyl-tRNA synthetase 
(ProRS) 
 TGME49_219850 93478 74 73 
40 
protein disulfide 
isomerase 
 TGME49_211680 52801 247 32 
41 
rhoptry kinase family 
protein ROP11 
(incomplete catalytic 
triad) (ROP11) 
 TGME49_227810 58034 97 27 
42 
rhoptry kinase family 
protein ROP40 
(incomplete catalytic 
triad) (ROP40) 
 TGME49_291960 57947 160 35 
43 
rhoptry neck protein 
RON4 (RON4) 
 TGME49_229010 107174 65 36 
44 
rhoptry protein ROP1 
(ROP1) 
 TGME49_309590 47994 259 56 
45 
rhoptry protein ROP15 
(ROP15) 
 TGME49_211290 36588 146 35 
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Table 3.1.  (continued) 
46 
rhoptry protein ROP2A 
(ROP2A) 
 TGME49_215785 49154 184 41 
47 
rhoptry protein ROP7 
(ROP7) 
 TGME49_295110 63394 52 18 
48 
rhoptry protein ROP8 
(ROP8) 
 TGME49_215775 65912 126 41 
49 
ribosomal protein RPL24 
(RPL24) 
 TGME49_244320 32693 35 21 
50 
ribosomal protein RPS13 
(RPS13) 
 TGME49_270380 17176 84 22 
51 
serine-threonine 
phosophatase 2C (PP2C) 
 TGME49_231850 36790 195 22 
52 
SWI2/SNF2-containing 
PHD finger protein 
 TGME49_236970 277892 35 160 
53 
translation elongation 
factor 2 family protein, 
putative 
 TGME49_205470 106571 104 62 
54 
translation initiation factor 
eIF-5A, putative 
 TGME49_251810 17468 323 25 
55 
tryptophanyl-tRNA 
synthetase (TrpRS2) 
 TGME49_288360 77057 67 46 
56 
dense granule protein 
GRA1 (GRA1) 
 TGME49_270250 20225 52 10 
57 
UBA/TS-N domain-
containing protein 
 TGME49_270595 849189 46 320 
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Bradyzoites related glycosylated proteins 
 
 The analysis of protein glycosylation of bradyzoites (table 3.2) mostly resulted in 
identification of 28 proteins out which 9 are hypothetical and 6 are putative. Identified 
proteins are mainly enzymes associated with translation and transcription and protein 
domains.  However, very little is known about the role of these proteins in Toxoplasma 
gondii and their function, structure or location is mostly inferred by homology.   
For example, DnaJ domain-containing protein is identified but its function is not 
known.  However, since DnaJ proteins are highly conserved in eukaryotes their function 
can be inferred for Toxoplasma gondii.  DnaJ in complex with HSP 40 play crucial roles 
in protein translation, folding, unfolding, translocation, and degradation.  
Transcription is a complex process that involves many enzymes as herein 
identified UvrD/REP helicase domain-containing protein involved in DNA damage and 
repair.  Transcription is initiated by RNA polymerase II apparatus but the role of 
identified mediator complex subunit MED14 is not explained for Toxoplasma gondii.  In 
humans this complex is a component of the mediator complex responsible for 
transcription regulation of almost all RNA polymerase II-dependent genes.  [102]  
Epsilon subunit of eukaryotic initiation factor-2B is identified as putative but it has an 
important role in regulating mRNA translation in eukaryotes.  TrmH family of proteins is 
involved in tRNA recognition and one of the members, RNA methyltransferase, is also 
identified. [103] 
 Mitochondrial proteins responsible for protein import are found in the earliest 
eukaryotes.  For that reason, even though mitochondrial inner membrane translocase 
subunit TIM17 is identified in this study as putative, its function can be narrowed down 
to either facilitator of the translocation of proteins across the inner membrane or 
facilitator of the insertion of proteins into the inner mitochondrial membrane.  [104] 
 Reversible protein phosphorylation is used for cellular information processing and 
has to be tightly controlled.  That is easier achieved by formation of complexes of kinases 
and other proteins.  One of such complexes is CMGC kinase group, identified here as 
putative.  [105] 
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As a part of S8 peptidase family, subtilisin SUB2 is a protease that contains a 
catalytic triad of serine, aspartate and histidine.   [106] 
Sec1 family protein is a part of Sec1/Munc18 (SM) family proteins that are 
essential for every vesicle fusion pathway.  [107] 
GYF domains are present in most eukaryotic species and recognize proline-rich 
sequences.  Even though not fully elucidated for Toxoplasma gondii, GYF domain-
containing protein is identified in this study.  [108] 
WD domain is found as a repeat in a large number of diverse eukaryotic proteins 
but what they have in common is folding into beta propeller that serves as a part of the 
platform used for reversible assembly of many protein complexes in almost all the major 
pathways.  G-beta repeat-containing protein is identified.   
Myosin K, identified in this study, is a part of motility system of Toxoplasma 
gondii, utilized for invasion as well as the escape from the host cells but also for general 
motility.  [109] 
Structural proteins such as clathrin and trichohyalin are also identified in this 
study but as putative. In humans clathrin is predominant component of polyhedral coat of 
coated pits and vesicles. Components of clathrin are 3 heavy chains and 3 light chains. 
Trichohyalin is responsible for organizing the intermediate filaments in human hair 
follicle inner root giving the shape to the hair fiber.  [110] 
 Even more importantly, out of 28 identified proteins 9 are hypothetical leaving a 
large part of glycosylated proteins under mysterious veil impossible even to infer.  
Interestingly one of the hypothetical proteins was identified with the highest score 
comparing to all other identified proteins. 
 However, one should keep in mind that these results are obtained from only one 
sample and not confirmed with replicates due to the lack of material.  This sample was 
obtained from brains of 26 mice with the total number of 7 x 104 cysts.  Total amount of 
protein was 1.6 mg and that amount was too small to divide in replicates.   
Also, results in the table 4.2 show low scores for the most proteins identified by 
the Mascot search engine. Even though all proteins above the threshold are identified 
with 95% confidence, proteins close to the threshold still have a high probability of being 
a random sequence.  
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 Putative proteins recognized in other organisms need to be further confirmed and 
characterized by studying mutant parasites lacking the relevant gene and identifying the 
proteins involved in their pathways.  
 
 
Conclusion 
 
 Even though ME49 strain is most prevalent in clinically diagnosed cases of 
toxoplasmosis, most proteomic studies are performed on RH strain because large 
quantities are easily obtained in tissue culture.  Moreover, bradyzoite stage of parasites 
life cycle, which develop in mice brains after approximately two to four weeks, is 
significantly less studied comparing to rapidly growing tachyzoite stage.  Considering all 
this, it is not surprising that the glycosylation machinery and its effects in Toxoplasma 
gondii are still largely unknown.  To that end, the aim of this study is to contribute to 
current knowledge database by identifying the possible candidates for the future studies.  
 In total 394 glycosylated tachyzoite proteins and 28 glycosylated bradyzoite 
proteins were identified utilizing the method developed in the chapter 2 of this 
dissertation.  Due to sample availability tachyzoite proteins were analyzed in triplicate 
and 57 out of 394 were identified in all replicates suggesting glycosylation as their post-
translational modification.  However, bradyzoites were studied utilizing only one sample 
due to the time required for their generation and the cost.  Nevertheless, 28 proteins were 
identified.  The lower number does not necessarily indicate low glycosylation but could 
also be due to low sample amount where majority of proteins are below the identification 
threshold of mass spectrometer.  For that reason, more experimental proof is required.   
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Table 4.2.  Proteins identified in tissue cysts. 
protein 
# 
protein name ID # mass 
Mowse 
score 
queries 
matched 
1 hypothetical protein TGME49_248160 122417 126 110 
2 
mediator complex subunit 
MED14 (MED14) 
 TGME49_229310 464457 41 165 
3 myosin K  TGME49_206415 262859 38 169 
4 Sec1 family protein  TGME49_271060 72640 37 47 
5 trichohyalin, putative  TGME49_242790 200679 37 102 
6 
DnaJ domain-containing 
protein 
 TGME49_313310 65713 35 60 
7 histone H4  TGME49_239260 11439 35 20 
8 hypothetical protein  TGME49_219218 175383 35 74 
9 
alpha-tubulin N-
acetyltransferase, putative 
 TGME49_319600 98566 35 68 
10 hypothetical protein  TGME49_253020 51621 34 26 
11 
UvrD/REP helicase 
domain-containing 
protein 
 TGME49_277550 342488 34 140 
12 
clathrin heavy chain, 
putative 
 TGME49_290950 194501 34 66 
13 
WD domain, G-beta 
repeat-containing protein 
 TGME49_213060 328236 34 127 
14 
eukaryotic initiation 
factor-2B, epsilon 
subunit, putative 
 TGME49_272640 92848 34 75 
15 
mitochondrial inner 
membrane translocase 
subunit TIM17, putative 
 TGME49_312220 22612 33 21 
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Table 3.2.  (continued) 
16 
DUF367 domain-
containing protein 
 TGME49_204540 63641 33 50 
17 CMGC kinase, putative  TGME49_250850 286625 33 123 
18 subtilisin SUB2 (SUB2)  TGME49_314500 141581 33 77 
19 hypothetical protein  TGME49_224830 121076 33 68 
20 
WD domain, G-beta 
repeat-containing protein 
 TGME49_272040 358195 33 91 
21 KRUF family protein  TGME49_251180 29178 33 20 
22 
GYF domain-containing 
protein 
 TGME49_298610 237893 33 132 
23 hypothetical protein  TGME49_306440 96284 33 37 
24 hypothetical protein  TGME49_231815 431546 33 240 
25 hypothetical protein  TGME49_210700 926533 32 420 
26 hypothetical protein  TGME49_259870 230595 32 128 
27 hypothetical protein  TGME49_233430 410963 32 207 
28 
RNA methyltransferase, 
TrmH family protein 
 TGME49_216390 89523 32 46 
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CHAPTER 5 
CONCLUSION 
 
 Toxoplasma gondii is intracellular parasite that has several life stages.  Humans 
are impacted by the two stages that allow asexual expansion of the parasite: tachyzoite 
and bradyzoite stages.  Tachyzoite is a rapidly growing stage responsible for 
dissemination during acute infection while bradyzoite is a slow growing stage when 
tissue cysts are formed. 
 Acute infection invokes the response of the host’s immune system and can be 
treated with combinations of antibiotics and antimalarial medications. Even though a 
large majority of tachyzoites are eliminated this way, a very few are required for the 
establishment of bradyzoites enclosed within the tissue cysts and responsible for the 
chronic phase of infection when the parasite becomes invisible for the host’s immune 
system.  This, so called, "dormant phase" has only recently been discovered to interfere 
with the host’s behavioral changes, most probably by altering neurotransmitter signal 
transduction and increasing the production of dopamine. [83] 
Although there are three types of lineages of Toxoplasma gondii (type I (RH and 
GT-1 strains), type II (ME49 strain) and type III (VEG strain)), the clinical cases of 
toxoplasmosis are most commonly due to type II (ME49) isolates.  ME49 strain, while 
significantly less virulent in mice, readily forms the cysts.  [111]  For that reason ME49 is 
chosen for the study described in this dissertation.   
Inferring form the genome of Toxoplasma gondii, it is believed that the parasite 
can express about 6500 proteins.  But 72 already identified proteins have no identified 
transcripts.  This can be attributed to posttranslational modifications that often have a 
functional significance and can help to understand the biology of the parasite.  [112]  
However, glycosylation of the proteome of Toxoplasma gondii is still largely unknown 
with even more scarce evidence of N-glycosylation.  Studies performed on RH strain of 
the parasite identified 26 N-glycosylated proteins indicating involvement of N-
glycosylation in gliding motility and host cell invasion.  [85]  Three of those 26 
glycoproteins were identified utilizing method developed in this dissertation.  Two 
rhoptry proteins of tachyzoites are associated with the invasion of the host cell, but the 
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third protein DnaJ was identified only in bradyzoites that were not analyzed in above 
mentioned study.   
However, one striking structural difference between tachyzoites and bradyzoites 
raises the question if the glycosylation plays a significant role in bradyzoite stage of 
parasite’s life.  That difference is the location of Golgi complex.   
In bradyzoites both endoplasmatic reticulum and Golgi complex are located near 
the basal end of the parasite.  However, in tachyzoites Golgi complex is located near to 
the apical end with numerous organelles separating it from endoplasmatic reticulum.  
[83]  Considering that N- and O-glycosylation take place in both endoplasmatic reticulum 
and Golgi complex, it would be hard to comprehend the significance of organelle 
separation if glycosylation played an important role in tachyzoites.  However, 
bradyzoites, developed from tachyzoites in the later stage of parasites life, have Golgi 
complex and endoplasmatic reticulum in close proximity.  One could speculate the 
importance of this movement and wonder if N- and/or O-glycosylation play a significant 
role in cyst formation or maintenance. 
In general, the array of glycans displayed on the surface of various viruses (HIV) 
or even cell types (blood group) can silence or induce the immune response of the host.  
Tachyzoite stage of Toxoplasma gondii is recognized by the host and induces the immune 
response that can be treated but bradyzoites are not recognized.  Current treatment of 
tachyzoites is not efficient enough and some of the surviving tachyzoites evolve into 
bradyzoite stage.  It is speculated that the parasite recruits some of the host proteins and 
uses them for its own growth and maintenance but that could also be the case with the 
glycans.  If the host’s glycans are displayed at the surface of the cyst the immune system 
would not recognize it as a foreign object.   
Figure 4.2, in chapter 4, represents the bradyzoites containing tissue cyst stained 
with two lectins, DBA and Con A.  DBA binds to N-acetyl-D-galactosamine (GalNAc) 
residues typical for O-linked glycoproteins but not found in N-linked glycoproteins, 
while Con A specifically recognizes the trimannoside core of N-linked glycans. It is 
obvious from the figure 4.2 that O-linked glycans are not observed anywhere within the 
cyst but are abundantly present on the cyst wall.  If the O-linked glycans were produced 
or transported in any vesicle within the cyst the green stain would be obvious, but it is 
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not.  This raises the question if O-linked glycans are recruited from the host thus making 
a parasite invisible to the host’s immune system.  
Glycosylation plays a crucial role in cell signaling.  Utilizing the method 
described in this dissertation, N-glycosylated proteins are identified in both tachyzoites 
and bradyzoites but only one glycoprotein is found in both groups and it is not yet 
annotated.  Considering parasite’s different morphology and the growth rate in these two 
life stages, different signaling pathways are easily envisioned.  However, the glycoprotein 
present in the both groups could be the key to understanding of the transition from 
tachyzoites to bradyzoites and provide the good target to prevent cyst formation and 
eliminate the parasite before it becomes invisible to the host’s immune system.   
In my opinion the key to successful eradication of infection caused by 
Toxoplasma gondii lays not so much in the recognition of the differences between 
tachyzoites and bradyzoites but their similarities.  If the tissue cysts recruit and display on 
their surface components derived from the host’s organism, damaging the tissue cyst 
would inevitably damage the host as well.  However, if one would identify components 
within the tachyzoites, while the parasite is still visible to the immune system and thus 
different then the host, then those components could possibly become the target for the 
treatment that would be least damaging for the host.  It would be fortunate to find such 
components among the proteins that are unique to the parasite but not present in the host.  
It was such notion that drove the development of this dissertation. 
Due to the growing body of evidence pointing out the importance of glycosylation 
of tachyzoites, the methods described in this dissertation were developed in an effort to 
provide an improvement of purification and enrichment of glycoproteins that 
subsequently could point out the candidate glycoproteins for future studies that will shed 
the light on the biology of Toxoplasma gondii and thus help develop means for 
toxoplasmosis eradication. 
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APPENDIX 
 
Table A.1. Proteins identified in two out of three replicates. 
protein 
# 
protein name ID # mass 
Mowse 
score 
queries 
matched 
1 
AMP-binding enzyme domain-
containing protein 
 TGME49_247760 86986 40 37 
2 calmodulin, putative  TGME49_269442 9780 75 10 
3 cyclin protein  TGME49_293280 273014 56 150 
4 
DDHD domain-containing 
protein 
 TGME49_313600 161510 32 108 
5 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide DDX39 (DDX39) 
 TGME49_216860 49113 51 24 
6 
dense granule protein GRA5 
(GRA5) 
 TGME49_286450 12838 92 11 
7 dihydropteroate synthase  TGME49_259550 82684 60 28 
8 
elongation factor 1-gamma, 
putative 
 TGME49_300140 44039 36 18 
9 
eukaryotic initiation factor-4A, 
putative 
 TGME49_250770 46673 58 47 
10 
GTP-binding nuclear protein 
ran/tc4 
 TGME49_248340 25997 41 22 
11 heat shock protein 90, putative  TGME49_244560 96822 79 62 
12 histone H2Ba  TGME49_305160 12602 197 55 
13 histone H2Bv  TGME49_209910 13732 197 44 
14 histone H3  TGME49_261240 15402 91 52 
15 hypothetical protein  TGME49_232120 222553 34 73 
16 hypothetical protein  TGME49_312420 117806 44 50 
17 hypothetical protein  TGME49_278960 58350 34 30 
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Table A.1. (continued) 
18 
nucleosome assembly protein 
(nap) protein 
 TGME49_244110 48586 38 25 
19 PEP-carboxykinase I  TGME49_289650 75342 84 38 
20 rhoptry protein ROP5 (ROP5)  TGME49_308090 61101 71 57 
21 
ribosomal protein RPS14 
(RPS14) 
 TGME49_263700 16301 53 33 
22 
ribosomal protein RPS30 
(RPS30) 
 TGME49_291850 6600 66 13 
23 
SF-assemblin/beta giardin 
protein 
 TGME49_307840 23344 37 21 
24 thioredoxin, putative  TGME49_209950 47699 43 47 
25 
microneme protein MIC1 
(MIC1) 
 TGME49_291890 48629 37 23 
26 
MRP family domain-containing 
protein 
 TGME49_318590 70666 57 27 
27 
heat shock protein HSP60 
(HSP60) 
 TGME49_247550 60913 107 49 
28 
HECT-domain (ubiquitin-
transferase) domain-containing 
protein 
 TGME49_275630 185550 39 64 
29 histone H3 centromeric CENH3  TGME49_225410 23282 47 39 
30 histone H3.3  TGME49_218260 15413 91 51 
31 hypothetical protein  TGME49_321410 212035 38 124 
32 hypothetical protein  TGME49_221220 213039 35 100 
33 hypothetical protein  TGME49_297210 444121 32 216 
34 hypothetical protein  TGME49_215980 24466 34 16 
35 
PIK3R4 kinase-related protein 
(incomplete catalytic triad) 
 TGME49_310190 317227 32 86 
36 protein kinase  TGME49_226540 54688 93 59 
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Table A.1. (continued) 
37 
regulator of chromosome 
condensation (RCC1) repeat-
containing protein 
 TGME49_310290 80702 40 74 
38 rhoptry protein ROP4 (ROP4)  TGME49_295125 42389 66 20 
39 
ribosomal protein RPL10A 
(RPL10A) 
 TGME49_215470 24603 33 20 
40 
SAG-related sequence SRS34A 
(SRS34A) 
 TGME49_271050 19106 59 6 
41 anonymous antigen-1, putative  TGME49_312630 286215 69 185 
42 
AP2 domain transcription factor 
AP2VIII-4 (AP2VIII4) 
 TGME49_272710 356669 43 242 
43 
ATPase family associated with 
various cellular activities (AAA) 
subfamily protein 
 TGME49_242625 976079 36 505 
44 
DEAD/DEAH box helicase 
domain-containing protein 
 TGME49_203840 196955 34 149 
45 dynein light chain, putative  TGME49_285350 25051 37 27 
46 
dynein, axonemal, heavy chain 2 
family protein 
 TGME49_235920 514463 49 335 
47 
EF-1 guanine nucleotide 
exchange domain-containing 
protein 
 TGME49_226410 36049 56 23 
48 
histone acetyltransferase 
TAF1/250 
 TGME49_276180 296268 33 151 
49 
histone family DNA-binding 
protein 
 TGME49_227970 25188 66 14 
50 histone H2AX  TGME49_261580 14510 35 28 
51 hypothetical protein  TGME49_221280 439285 33 284 
52 hypothetical protein  TGME49_240060 88532 69 48 
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Table A.1. (continued) 
53 hypothetical protein  TGME49_239410 256130 39 198 
54 hypothetical protein  TGME49_205130 518657 37 277 
55 hypothetical protein  TGME49_203980 201277 44 78 
56 hypothetical protein  TGME49_230350 138895 35 79 
57 hypothetical protein  TGME49_228070 441563 37 240 
58 hypothetical protein  TGME49_315610 15971 132 48 
59 hypothetical protein  TGME49_316470 363875 36 148 
60 hypothetical protein  TGME49_276860 55516 34 37 
61 NAC domain-containing protein  TGME49_257090 38782 56 26 
62 
poly(ADP-ribose) 
glycohydrolase 
 TGME49_280380 61836 47 42 
63 
Pumilio-family RNA binding 
repeat-containing protein 
 TGME49_260600 172516 37 81 
64 
ribosomal protein RPL12 
(RPL12) 
 TGME49_254440 17821 38 14 
65 ribosomal protein RPP2 (RPP2)  TGME49_309810 11768 43 21 
66 
ribosomal protein RPS12 
(RPS12) 
 TGME49_205340 15399 67 9 
67 RNA methyltransferase  TGME49_218580 310819 73 111 
68 
RNA recognition motif-
containing protein 
 TGME49_262620 31760 58 63 
69 
SAG-related sequence SRS22F 
(SRS22F) 
 TGME49_238500 19504 39 9 
70 
translation initiation factor IF-2, 
putative 
 TGME49_214270 126067 35 91 
71 
XRN 5'-3' exonuclease N-
terminus protein 
 TGME49_242830 223762 35 107 
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Table A.2.  Proteins identified in one out of three replicates. 
protein 
# 
protein name ID # mass 
Mowse 
score 
queries 
matched 
1 
2-oxo acid dehydrogenases 
acyltransferase (catalytic domain) 
domain-containing protein 
 TGME49_31
9920 
70289 34 35 
2 
3-hydroxyisobutyrate 
dehydrogenase 
 TGME49_26
3430 
34159 35 26 
3 
5'-3' exonuclease, N-terminal 
resolvase family domain-containing 
protein 
 TGME49_28
4010 
124798 34 75 
4 ABC transporter, putative 
 TGME49_20
8050 
381288 39 224 
5 ABC1 family protein 
 TGME49_21
3620 
211215 41 135 
6 
acetyltransferase, GNAT family 
protein 
 TGME49_30
5450 
56862 40 36 
7 
adaptin c-terminal domain-
containing protein 
 TGME49_27
2600 
182951 32 93 
8 
AMP-binding enzyme domain-
containing protein 
 TGME49_31
0080 
87847 42 46 
9 
AMP-binding enzyme domain-
containing protein 
TGME49_21
9230 
87016 36 34 
10 
AP2 domain transcription factor 
AP2III-4 (AP2III4) 
 TGME49_29
9020 
171537 38 112 
11 
AP2 domain transcription factor 
AP2V-2 (AP2V2) 
 TGME49_28
5895 
365853 38 167 
12 arginyl-tRNA synthetase 
 TGME49_27
0690 
130254 34 99 
 
110 
 
Table A.2. (continued) 
13 argonaute AGO (AGO) 
 TGME49_31
0160 
105190 34 75 
14 beta tubulin 
 TGME49_26
6960 
50073 61 44 
15 beta-tubulin, putative 
 TGME49_22
1620 
50037 61 45 
16 
bifunctional GMP 
synthase/glutamine 
amidotransferase protein 
 TGME49_23
0450 
62294 34 41 
17 Brf1p family coiled coil protein 
 TGME49_23
2440 
54044 34 76 
18 
calcium dependent protein kinase 
CDPK7 (CDPK7) 
 TGME49_22
8750 
219083 34 95 
19 
calcium dependent protein kinase 
CDPK8 (CDPK8) 
 TGME49_29
2055 
161419 36 77 
20 
cAMP-dependent protein kinase 
regulatory subunit 
 TGME49_24
2070 
42796 35 42 
21 
cell-cycle-associated protein kinase, 
putative 
 TGME49_28
1450 
50168 36 44 
22 ClpB, putative 
 TGME49_27
5690 
114549 36 80 
23 
cold-shock DNA-binding domain-
containing protein 
 TGME49_32
0600 
23060 87 21 
24 CRIPT, putative 
 TGME49_25
0350 
10076 32 7 
25 cyclin protein 
 TGME49_29
3280 
273014 68 181 
26 cyclophilin 
 TGME49_22
1210 
19604 48 24 
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Table A.2. (continued) 
27 cyclophilin precursor 
 TGME49_20
5700 
38196 49 31 
28 
D-3-phosphoglycerate 
dehydrogenase 
 TGME49_23
9820 
65193 58 3 
29 
DEAD/DEAH box helicase domain-
containing protein 
 TGME49_26
4160 
120180 33 62 
30 DEAD-family helicase 
 TGME49_29
8020 
130966 33 80 
31 
dense granule protein GRA3 
(GRA3) 
 TGME49_22
7280 
23875 58 16 
32 
DNA-dependent RNA polymerase 
(POLRMT) 
 TGME49_24
6060 
232348 37 123 
33 DnaJ family chaperone, putative 
 TGME49_31
1240 
47448 33 39 
34 DnaK family protein 
 TGME49_22
6830 
103191 41 49 
35 elongation factor TS protein 
 TGME49_20
9010 
52348 37 26 
36 
endonuclease/exonuclease/phosphat
ase domain-containing protein 
 TGME49_23
8400 
290205 40 141 
37 
endonuclease/exonuclease/phosphat
ase family protein 
 TGME49_25
9560 
164511 42 54 
38 enolase 1 
 TGME49_26
8860 
48341 36 25 
39 enolase 2 
 TGME49_26
8850 
52113 36 32 
40 ERCC4 domain-containing protein 
 TGME49_30
5310 
223459 40 136 
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Table A.2. (continued) 
41 
ethylene-responsive RNA helicase, 
putative 
 TGME49_31
3240 
85533 34 43 
42 
eukaryotic aspartyl protease 
superfamily protein 
 TGME49_20
9620 
43488 33 16 
43 
eukaryotic initiation factor-2 
gamma, putative 
 TGME49_23
5970 
50508 39 26 
44 
eukaryotic translation initiation 
factor 3 subunit 7, putative 
 TGME49_31
7720 
68766 39 62 
45 
Fe-S metabolism associated 
domain-containing protein 
 TGME49_27
7010 
36177 32 31 
46 FHA domain-containing protein 
 TGME49_26
7600 
84416 33 47 
47 
FUSE-binding protein 2 / KH-type 
splicing regulatory protein (FUBP2) 
 TGME49_21
6670 
100093 43 99 
48 
glucose-6-phosphate 1-
dehydrogenase 
 TGME49_29
4200 
62736 39 47 
49 
glutamine synthetase, type I, 
putative 
 TGME49_27
3490 
65146 35 49 
50 
glutaminyl-tRNA synthetase 
(GlnRS) 
 TGME49_21
7460 
95526 34 57 
51 
glycine cleavage T-protein 
(aminomethyl transferase) domain-
containing protein 
 TGME49_28
3820 
195707 36 96 
52 GTPase RAB7 (RAB7) 
 TGME49_24
8880 
47712 35 33 
53 guanylyl cyclase 
 TGME49_25
4370 
477032 39 161 
54 HEAT repeat-containing protein 
 TGME49_24
4040 
132694 32 39 
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Table A.2. (continued) 
55 HEAT repeat-containing protein 
 TGME49_22
9180 
136163 39 595 
56 heat shock protein 
 TGME49_25
1780 
78250 38 85 
57 
HECT-domain (ubiquitin-
transferase) domain-containing 
protein 
 TGME49_29
5710 
851243 46 475 
58 helicase, putative 
 TGME49_20
9770 
150821 35 68 
59 
helix-hairpin-helix motif domain-
containing protein 
 TGME49_28
5490 
117256 37 64 
60 
histone lysine methyltransferase, 
SET, putative 
 TGME49_20
1250 
177893 39 114 
61 
HMG (high mobility group) box 
domain-containing protein 
 TGME49_21
9828 
11381 50 34 
62 hypothetical protein 
 TGME49_32
6600 
17775 32 46 
63 hypothetical protein 
 TGME49_29
4860 
254850 38 109 
64 hypothetical protein 
 TGME49_29
5370 
29729 32 21 
65 hypothetical protein 
 TGME49_29
3252 
166690 41 64 
66 hypothetical protein 
 TGME49_29
3560 
229122 37 66 
67 hypothetical protein 
 TGME49_20
9470 
57616 39 18 
68 hypothetical protein 
 TGME49_22
0890 
51195 36 28 
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Table A.2. (continued) 
69 hypothetical protein 
 TGME49_22
1560 
58420 50 54 
70 hypothetical protein 
 TGME49_22
2060 
103670 34 70 
71 hypothetical protein 
 TGME49_22
2250 
167959 36 109 
72 hypothetical protein 
 TGME49_25
3990 
231484 41 101 
73 hypothetical protein 
 TGME49_29
9270 
119375 34 65 
74 hypothetical protein 
 TGME49_29
9130 
346626 38 210 
75 hypothetical protein 
 TGME49_27
6200 
448604 36 317 
76 hypothetical protein 
 TGME49_21
1700 
273962 35 124 
77 hypothetical protein 
 TGME49_26
5470 
43627 36 39 
78 hypothetical protein 
 TGME49_26
5280 
133185 37 66 
79 hypothetical protein 
 TGME49_26
4890 
199927 36 106 
80 hypothetical protein 
 TGME49_27
9380 
34769 73 24 
81 hypothetical protein 
 TGME49_28
9520 
355979 39 137 
82 hypothetical protein 
 TGME49_28
9970 
24448 53 24 
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Table A.2. (continued) 
83 hypothetical protein 
 TGME49_29
0310 
200813 34 138 
84 hypothetical protein 
 TGME49_29
0620 
296416 37 187 
85 hypothetical protein 
 TGME49_29
2360 
117449 35 47 
86 hypothetical protein 
 TGME49_26
7670 
90813 35 51 
87 hypothetical protein 
 TGME49_21
3635 
325486 33 145 
88 hypothetical protein 
 TGME49_28
6510 
53152 35 20 
89 hypothetical protein 
 TGME49_28
5820 
19055 35 21 
90 hypothetical protein 
 TGME49_24
0980 
151943 33 83 
91 hypothetical protein 
 TGME49_24
3310 
132517 32 82 
92 hypothetical protein 
 TGME49_24
3780 
91568 42 47 
93 hypothetical protein 
 TGME49_24
4120 
248641 34 194 
94 hypothetical protein 
 TGME49_23
9340 
211263 36 145 
95 hypothetical protein 
 TGME49_20
5320 
70849 33 36 
96 hypothetical protein 
 TGME49_20
3362 
24667 36 16 
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Table A.2. (continued) 
97 hypothetical protein 
 TGME49_20
3090 
60624 34 63 
98 hypothetical protein 
 TGME49_20
2170 
94060 33 32 
99 hypothetical protein 
 TGME49_26
1740 
14158 40 10 
100 hypothetical protein 
 TGME49_26
1390 
28567 34 14 
101 hypothetical protein 
 TGME49_25
8670 
187479 41 94 
102 hypothetical protein 
 TGME49_25
8420 
259194 35 101 
103 hypothetical protein 
 TGME49_25
8170 
43915 35 27 
104 hypothetical protein 
 TGME49_26
3200 
118612 35 61 
105 hypothetical protein 
 TGME49_26
3080 
14407 91 10 
106 hypothetical protein 
 TGME49_23
0950 
240359 37 91 
107 hypothetical protein 
 TGME49_23
1200 
298665 37 141 
108 hypothetical protein 
 TGME49_22
9390 
103131 39 40 
109 hypothetical protein 
 TGME49_22
9750 
146074 33 83 
110 hypothetical protein 
 TGME49_26
9413 
11746 41 6 
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Table A.2. (continued) 
111 hypothetical protein 
 TGME49_26
8950 
60196 35 25 
112 hypothetical protein 
 TGME49_23
0180 
57330 34 26 
113 hypothetical protein 
 TGME49_22
6690 
113185 37 65 
114 hypothetical protein 
 TGME49_22
6320 
73663 36 22 
115 hypothetical protein 
 TGME49_22
5380 
51498 36 56 
116 hypothetical protein 
 TGME49_22
5130 
148061 40 74 
117 hypothetical protein 
 TGME49_22
8630 
34812 115 23 
118 hypothetical protein 
 TGME49_22
4320 
262381 39 156 
119 hypothetical protein 
 TGME49_22
3760 
168702 32 87 
120 hypothetical protein 
 TGME49_22
3725 
449056 32 188 
121 hypothetical protein 
 TGME49_22
3500 
120960 34 66 
122 hypothetical protein 
 TGME49_23
4250 
248625 35 182 
123 hypothetical protein 
 TGME49_23
4590 
30345 38 28 
124 hypothetical protein 
 TGME49_23
5580 
79102 33 62 
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Table A.2. (continued) 
125 hypothetical protein 
 TGME49_23
6800 
52349 36 22 
126 hypothetical protein 
 TGME49_23
7195 
99915 44 45 
127 hypothetical protein 
 TGME49_22
8065 
10166 34 6 
128 hypothetical protein 
 TGME49_21
4950 
21501 36 2 
129 hypothetical protein 
 TGME49_21
5030 
199439 33 62 
130 hypothetical protein 
 TGME49_31
0790 
24708 51 28 
131 hypothetical protein 
 TGME49_31
1270 
203341 34 108 
132 hypothetical protein 
 TGME49_31
2500 
169890 39 113 
133 hypothetical protein 
 TGME49_31
2580 
96685 34 48 
134 hypothetical protein 
 TGME49_31
2905 
261708 41 202 
135 hypothetical protein 
 TGME49_31
3340 
161141 36 187 
136 hypothetical protein 
 TGME49_31
3430 
593550 43 219 
137 hypothetical protein 
 TGME49_24
6190 
530021 37 228 
138 hypothetical protein 
 TGME49_24
6580 
42820 35 27 
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Table A.2. (continued) 
139 hypothetical protein 
 TGME49_24
7520 
26535 34 9 
140 hypothetical protein 
 TGME49_30
7860 
434056 42 235 
141 hypothetical protein 
 TGME49_25
0090 
88129 35 52 
142 hypothetical protein 
 TGME49_21
9640 
197263 34 153 
143 
Kazal-type serine protease inhibitor 
domain-containing protein 
 TGME49_22
4080 
214943 33 83 
144 kelch repeat-containing protein 
 TGME49_26
4940 
214243 33 81 
145 kelch repeat-containing protein 
 TGME49_22
9290 
104328 37 39 
146 kinesin, putative 
 TGME49_28
6660 
76150 36 30 
147 
lactate dehydrogenase LDH1 
(LDH1) 
 TGME49_23
2350 
35548 32 56 
148 
lactate dehydrogenase LDH2 
(LDH2) 
 TGME49_29
1040 
35334 43 44 
149 
leucine rich repeat-containing 
protein 
 TGME49_26
2530 
108056 34 29 
150 leucyl aminopeptidase LAP (LAP) 
 TGME49_29
0670 
83236 34 68 
151 lipase 
 TGME49_26
9300 
126439 35 82 
152 
long-chain fatty acid CoA ligase, 
putative 
 TGME49_24
3800 
83507 49 53 
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Table A.2. (continued) 
153 
mannosyl-oligosaccharide 
glucosidase 
 TGME49_24
2020 
151503 33 47 
154 MC family transporter, putative 
 TGME49_20
8790 
33687 53 26 
155 Met-10+ like-protein 
 TGME49_24
3280 
98907 35 74 
156 methyltransferase MTA70, putative 
 TGME49_21
7350 
87997 39 49 
157 microneme protein MIC2 (MIC2) 
 TGME49_20
1780 
82633 34 43 
158 MoaC family protein 
 TGME49_24
0930 
41013 35 38 
159 Mpv17 / PMP22 family protein 
 TGME49_27
3290 
93582 33 54 
160 
Myb family DNA-binding domain-
containing protein 
 TGME49_32
1450 
437016 33 237 
161 myosin A 
 TGME49_23
5470 
93319 36 52 
162 myosin D 
 TGME49_26
3180 
91051 36 82 
163 
Nin one binding (NOB1) Zn-ribbon 
family protein 
 TGME49_21
8570 
61202 43 37 
164 
non-specific serine/threonine protein 
kinase 
 TGME49_26
8370 
904528 36 419 
165 
Not1 N-terminal domain, CCR4-Not 
complex component protein 
 TGME49_23
3020 
83853 34 34 
166 notchless, putative 
 TGME49_21
5740 
57710 59 23 
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Table A.2. (continued) 
167 
oxidoreductase, short chain 
dehydrogenase/reductase family 
protein 
 TGME49_31
3050 
40367 36 30 
168 PCI domain-containing protein 
 TGME49_29
2220 
61439 45 45 
169 PCI domain-containing protein 
 TGME49_21
7820 
51722 55 23 
170 PDI family protein 
 TGME49_23
2410 
24909 35 18 
171 
peptidase M16 family potein, 
putative 
 TGME49_23
6210 
56915 36 38 
172 
peptidase M16 inactive domain-
containing protein 
 TGME49_22
7948 
142762 34 74 
173 peroxiredoxin PRX3 (PRX3) 
 TGME49_23
0410 
30534 59 11 
174 phosphatidylinositol 3- and 4-kinase 
 TGME49_26
6010 
963722 35 519 
175 phosphatidylinositol 3- and 4-kinase 
 TGME49_21
5700 
316905 36 133 
176 phosphatidylserine decarboxylase 
 TGME49_26
9920 
107987 34 79 
177 
phospholipase, patatin family 
protein 
 TGME49_21
2130 
109733 35 60 
178 phospholipase/carboxylesterase 
 TGME49_25
4690 
54235 33 29 
179 
proliferation-associated protein 
2G4, putative 
 TGME49_27
9390 
50341 33 20 
180 proteasome 26S regulatory subunit 
 TGME49_31
3410 
117708 42 82 
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Table A.2. (continued) 
181 protein kinase 
 TGME49_23
9420 
183676 37 73 
182 
protein phosphatase 2C domain-
containing protein 
 TGME49_20
1630 
41457 32 31 
183 
protein phosphatase 2C domain-
containing protein 
 TGME49_20
1520 
42094 32 35 
184 
protein phosphatase 2C domain-
containing protein 
 TGME49_23
2340 
59867 83 31 
185 
protein phosphatase 2C domain-
containing protein 
 TGME49_27
0320 
58674 61 49 
186 Rad9 protein 
 TGME49_25
5430 
88589 35 53 
187 RAP domain-containing protein 
 TGME49_23
9350 
297817 37 112 
188 RAP domain-containing protein 
 TGME49_23
7100 
181991 38 99 
189 
RecF/RecN/SMC N terminal 
domain-containing protein 
 TGME49_25
7180 
181309 35 99 
190 rhoptry neck protein RON5 (RON5) 
 TGME49_31
1470 
187408 33 103 
191 rhoptry protein ROP16 (ROP16) 
 TGME49_26
2730 
76215 36 37 
192 ribonuclease type III Dicer 
 TGME49_26
7030 
491971 39 171 
193 ribosomal L37ae family protein 
 TGME49_32
5400 
13049 44 11 
194 ribosomal protein RPL11 (RPL11) 
 TGME49_30
9820 
20199 52 10 
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Table A.2. (continued) 
195 ribosomal protein RPL14 (RPL14) 
 TGME49_26
7060 
17878 40 13 
196 ribosomal protein RPL17 (RPL17) 
 TGME49_29
9050 
22269 69 25 
197 
ribosomal protein RPL23A 
(RPL23A) 
 TGME49_23
8010 
18561 37 24 
198 ribosomal protein RPL3 (RPL3) 
 TGME49_22
7360 
44056 55 50 
199 
ribosomal protein RPL37A 
(RPL37A) 
 TGME49_30
0190 
10404 44 20 
200 ribosomal protein RPL4 (RPL4) 
 TGME49_30
9120 
49258 54 55 
201 ribosomal protein RPL6 (RPL6) 
 TGME49_31
3390 
31222 111 23 
202 ribosomal protein RPL7 (RPL7) 
 TGME49_31
4810 
30121 43 26 
203 ribosomal protein RPP0 (RPP0) 
 TGME49_21
8410 
34157 75 27 
204 ribosomal protein RPS10 (RPS10) 
 TGME49_27
5810 
17398 41 19 
205 ribosomal protein RPS11 (RPS11) 
 TGME49_22
6970 
18677 41 20 
206 ribosomal protein RPS17 (RPS17) 
 TGME49_20
7840 
15228 99 21 
207 ribosomal protein RPS18 (RPS18) 
 TGME49_22
5080 
17722 46 13 
208 ribosomal protein RPS2 (RPS2) 
 TGME49_30
5520 
29336 46 21 
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Table A.2. (continued) 
209 ribosomal protein RPS20 (RPS20) 
 TGME49_22
3050 
25899 83 27 
210 ribosomal protein RPS25 (RPS25) 
 TGME49_23
1140 
18682 46 9 
211 ribosomal protein RPS26 (RPS26) 
 TGME49_24
3570 
12725 42 7 
212 ribosomal protein RPS28 (RPS28) 
 TGME49_20
9290 
13214 61 11 
213 ribosomal protein RPS4 (RPS4) 
 TGME49_20
7440 
35507 74 55 
214 ribosomal protein RPS7 (RPS7) 
 TGME49_23
9100 
22587 47 19 
215 ribosomal protein RPSA (RPSA) 
 TGME49_26
6060 
31512 45 19 
216 
ribosomal-ubiquitin protein 
RPS27A (RPS27A) 
 TGME49_24
5620 
17321 53 15 
217 
RNA polymerase-associated protein 
RTF1 (RTF1) 
 TGME49_24
4210 
84698 35 58 
218 
RNA recognition motif-containing 
protein 
 TGME49_32
1500 
50938 40 57 
219 
RNA recognition motif-containing 
protein 
 TGME49_21
1420 
20398 64 14 
220 
RNA recognition motif-containing 
protein 
 TGME49_32
0100 
128921 32 105 
221 
RNA recognition motif-containing 
protein 
 TGME49_26
5250 
160178 34 149 
222 
RNA recognition motif-containing 
protein 
 TGME49_26
4610 
44974 37 26 
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Table A.2. (continued) 
223 
RNA recognition motif-containing 
protein 
 TGME49_29
1930 
73117 35 93 
224 rRNA pseudouridine synthase 
 TGME49_21
4210 
56744 43 45 
225 
SAG-related sequence SRS14A 
(SRS14A) 
 TGME49_25
4060 
40805 34 19 
226 
SAG-related sequence SRS29C 
(SRS29C) 
 TGME49_23
3480 
39119 83 17 
227 Sec1 family protein 
 TGME49_24
0740 
71938 33 34 
228 
site-specific recombinase, phage 
integrase family protein 
 TGME49_25
9230 
112628 34 88 
229 SNARE associated Golgi protein 
 TGME49_27
9370 
46581 37 28 
230 STE kinase 
 TGME49_22
5960 
412543 36 171 
231 subtilisin SUB2 (SUB2) 
 TGME49_31
4500 
141581 34 67 
232 
surp module domain-containing 
protein 
 TGME49_24
6500 
71701 34 36 
233 
sushi domain (scr repeat) domain-
containing protein 
 TGME49_22
3480 
507026 38 274 
234 syntaxin protein 
 TGME49_20
9820 
73624 38 39 
235 TBC domain-containing protein 
 TGME49_20
3910 
228838 34 115 
236 
T-complex protein 10 C-terminus 
protein 
 TGME49_25
8710 
190704 35 108 
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Table A.2. (continued) 
237 
tetratricopeptide repeat-containing 
protein 
 TGME49_30
5150 
153101 32 85 
238 
tetratricopeptide repeat-containing 
protein 
 TGME49_24
2360 
80215 33 46 
239 
tetratricopeptide repeat-containing 
protein 
 TGME49_24
9480 
126391 32 109 
240 Toxoplasma gondii family E protein 
 TGME49_24
0360 
51331 39 49 
241 transmembrane protein 
 TGME49_31
3930 
94912 65 51 
242 
tRNA ligases class II (D, K and N) 
domain-containing protein 
 TGME49_22
0350 
127446 36 63 
243 
Tubulin-tyrosine ligase family 
protein 
 TGME49_22
8410 
125827 32 70 
244 
UvrD/REP helicase domain-
containing protein 
 TGME49_27
7550 
342488 33 124 
245 Vps52 / Sac2 family protein 
 TGME49_25
8832 
86819 33 59 
246 
V-type H(+)-translocating 
pyrophosphatase VP1 
 TGME49_24
8670 
85295 35 25 
247 
WD domain, G-beta repeat-
containing protein 
 TGME49_31
5140 
155379 37 72 
248 
zinc finger (CCCH type) motif-
containing protein 
 TGME49_25
0690 
368046 34 161 
249 
zinc finger, C3HC4 type (RING 
finger) domain-containing protein 
 TGME49_21
5640 
160053 37 53 
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